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Influenza B virus causes a respiratory disease in people with a compromised 
immune system. The NS1B protein of influenza B virus is essential for virus growth and 
plays a crucial role in inhibiting the anti-viral responses mounted by the infected host 
cell. The N terminal 104 amino acids of NS1B bind a cellular protein called ISG15. 
ISG15 is an interferon induced ‘ubiquitin-like’ protein, and upon interferon induction, is 
conjugated to hundreds of targets. It has been found that both ISG15 and its conjugation 
inhibit many viruses. The focus of the current study was to characterize the interaction 
between NS1B and ISG15. Study of a recombinant influenza B virus which encoded a 
mutant NS1B protein that is unable to bind ISG15 revealed that ISG15 is mis-localized in 
cells infected with wild type but not the mutant influenza B virus. Further, such a mutant 
virus is attenuated in growth as compared to wild type virus in human cell lines but is not 
attenuated in canine cell lines. This result led to the discovery of the species specific 
vii 
 
nature of the interaction between NS1B and ISG15. Specifically, NS1B was found to 
bind ISG15 homologs from human and old world monkeys like Rhesus macaques and 
African green monkeys but not those from mouse or canines. These findings were 
extended by identifying the hinge between the N and C terminal domains of ISG15 as 
one of the major determinants of species specificity. These results highlight the 
importance of using human or primate cell culture models to study the effect of ISG15 on 
influenza B virus, and raises new possibilities on differences in the function of the ISG15 
system in different species. 
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CHAPTER 1: Literature Review 
1.1  INFLUENZA VIRUSES 
 
 
Influenza is a common respiratory illness, seen in 5-20% of the U.S population. 
The three types of influenza viruses are A, B and C. While influenza A virus causes 
infection in a wide variety of mammals and birds, influenza B and C are mostly human 
viruses. However, recently influenza B was discovered in seals (Osterhaus, 
Rimmelzwaan et al. 2000) and influenza C has also been isolated from swine in China 
(Yuanji and Desselberger 1984). In humans, the common symptoms of influenza 
infection are cold, chills, fever, muscle pain, sore throat, headache, coughing, and general 
discomfort (http://www.cdc.gov/flu/). Although influenza virus infection causes mild 
symptoms, influenza A viruses can cause a pandemic, resulting in widespread death, like 
the 1918 ‘Spanish flu’, in which approximately 40 million people died worldwide. 
Influenza A viruses mutate at a high rate; therefore the strains vary every year making 
lasting immunity impossible. The limited host range of influenza B virus ensures that 
pandemics do not occur. However, influenza B causes a disease in people with a 
weakened immune system, like very young children or very old people 
(http://www.cdc.gov/flu/). 
1.2  STRUCTURE AND PROTEINS OF INFLUENZA VIRUS: 
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Influenza viruses belong to the Orthomyxoviridae family of RNA viruses. In 
addition to influenza A, B and C viruses, this family also contains the genus Thogotovirus 
(sometimes referred to as influenza D). Influenza viruses are enveloped, negative sense, 
segmented RNA viruses, whose genome comprises 8 RNA segments for influenza A and 
B viruses and 7 segments for influenza C virus (Lamb and Krug 2001). Influenza A and 
B viruses are indistinguishable from each other morphologically; however influenza C 
virus can be distinguished because of the different arrangement of its glycoprotein spikes 
(summarized from (Lamb and Krug 2001)).  Influenza viruses are pleiomorphic, usually 
50-12nm in diameter. Viruses amplified in bird eggs or in tissue culture are more uniform 
and spherical; however those isolated from animals and humans show more variation in 
shape and filamentous forms might occur (ICTVdB, ver. 4). The viral genes that 
determine the morphology of the virus are not known. 
The structure of influenza B virus is shown in figure 1.1 (Lamb and Krug 2001). 
The outermost layer of influenza virion is the viral envelope, which is derived from the 
host plasma membrane through budding. From the envelope of the virus, glycoproteins 
that form spikes radiate outwards. In influenza A and B viruses, these spikes are made up 
of two viral glycoproteins, the rod shaped haemagluttinin (HA) and mushroom shaped 
neuraminidase (NA), encoded by the viral RNA segments 4 and 6 respectively. HA is 
required for receptor recognition (reviewed in (Skehel and Wiley 2000), (Whittaker 
2001)) and release of viral ribonucleoproteins (RNPs) from the viral envelope into the 
cytoplasm of the host cell (Whittaker 2001). NA is responsible for viral release from the 




Figure 1.1  Structure and proteins of influenza B virus. The location of the structural 
proteins, viral envelope, matrix and eight genomic RNA segments are 
shown. The NS1B protein is present only in the infected cell. Adapted from 







Besides playing important roles in the viral life cycle, HA and NA are also important 
antigenic determinants of the virus. Influenza C has a single glycoprotein, which 
combines all the above activities (Krug and Lamb 2001). This protein is called HEF, 
which stands for haemaglutinin, esterase and fusion. Another integral membrane protein 
present on the virion is the M2, BM2 or CM2 protein of influenza A, B and C viruses 
respectively. These proteins are encoded by the RNA segment 7 of influenza A and B 
viruses and segment 6 of influenza C virus. The M2 and BM2 proteins of influenza A and 
B viruses respectively are ion channel proteins which play important roles in the un-
coating of the viral RNPs (Pinto and Lamb 2006).  Influenza B virus contains another 
small integral membrane protein, called NB, which is encoded by the bicistronic segment 
6, which also encodes NA. An equivalent of NB has not been discovered in influenza A 
virus, and its function has yet to be fully understood. Beneath the viral envelope lies the 
viral matrix protein (M1). The M1 protein is the most abundant protein present in the 
virion and forms connections with both the membrane bound HA and NA molecules as 
well as the core RNPs. Associated with the M1 protein is the nuclear export protein 
(NEP), also called the non-structural protein 2 (NS2), which is involved in the nuclear 
export of viral RNPs (O'Neill, Talon et al. 1998). The core of the virion is made up of 
viral RNP complexes, which contain the viral RNA segments, Nucleoprotein (NP), 
encoded by RNA segment 5 and the three subunits of the viral polymerase, PA, PB1 and 
PB2, encoded by the segments 3, 2 and 1 respectively. In the virion, each RNA segment 
is coated with the NP, and the ends are looped back and bound to the viral polymerase 








Figure 1.2  Structure of influenza viral RNP in the virion. Blue spheres represent NP 
monomers binding vRNA (black line). The vRNA is looped back and forms 
a hairpin structure with a duplex (of 5’ and 3’ ends of vRNA) which forms 








The RNA segments encode 12 and 11 proteins in influenza A and B viruses and 10 for 
influenza C. One viral protein, the non-structural protein 1 (NS1) is not present in the 
virion and is exclusively present in the infected cells of the host. NS1 is encoded by RNA 
segment 8 and is important to thwart the host’s anti viral response. Another protein, PB2-
F2, encoded by segment 1, has been found in cells infected with influenza A but not B 
virus. This protein is thought to be involved in apoptotic responses to infection 
(summarized from (Lamb and Krug 2001).  
1.3 THE INFLUENZA VIRUS LIFE CYCLE 
 
The influenza virus life cycle is depicted in figure 1.3 (Lamb and Krug 2001). 
Briefly, the virus attaches to receptors on the cell surface though it’s HA, which results in 
endocytosis of the virus. Inside the endocytic vesicle, viral proteins HA and M2 mediate 
vesicle-viral membrane fusion, releasing the viral RNPs into the cytoplasm of the host 
cell, from where they are imported into the nucleus. The genome transcription and 
replication take place in the nucleus of the infected cell, involving the viral polymerase, 
NP and NS1 proteins. The newly assembled vRNPs are then exported from the nucleus 
by NEP and M1. Viral assembly is facilitated by the membrane proteins, HA, NA and 
M2 along with M1 and takes place in specialized regions of the plasma membrane called 
‘lipid rafts’, which are concentrated in viral glycoproteins. Finally the virus is pinched off 
the plasma membrane of the infected cell by budding. Each of these steps in the viral life 




Figure 1.3   Life cycle of influenza virus. The virus is endocytosed into the cell, and in a 
pH dependent step, the vRNP is uncoated from the viral envelope. 
Replication takes place inside the nucleus. Virus assembly and budding take 
place in regions of the plasma membrane known as lipid rafts. See text for 






1.3.1 Virus binding to receptor 
 
The receptors for influenza virus is the terminal N acetyl neuraminic acid (sialic 
acid) present on glycolipids and glycoproteins. The viral protein responsible for 
recognizing and binding the receptors is the HA, which is present on the viral envelope. 
The HA molecule is synthesized as HA0 precursor peptide which is cleaved into HA1 
and HA2 peptides. HA is a trimer, and can exist in three conformations: the un-cleaved 
HA0, the cleaved HA1 and HA2 at neutral pH and the pH induced altered conformation 
of HA1 and HA2 (summarized from (Lamb and Krug 2001)). The cleavage of HA is an 
essential step in the life cycle of the virus; in the absence of HA cleavage, a multiple 
cycle growth of influenza virus cannot be achieved (Lazarowitz and Choppin 1975), 
(Klenk, Rott et al. 1975). By recognizing the cellular receptors, HA also determines the 
host range of influenza viruses (reviewed in (Skehel and Wiley 2000), (Whittaker 2001)). 
The HAs isolated from different influenza A viruses differ in their ability to recognize 
different cellular receptors in which the sialic acid is either alpha (2,6) or alpha(2,3) 
linked. HA from influenza A viruses isolated from avian or equine sources recognize the 
alpha (2, 3) linked sialic acid chains, HA from human influenza A viruses recognize 
alpha (2, 6) linked chains and those isolated from swine recognize both (Ito 2000). HA 
from influenza B viruses (which predominantly infect only humans in nature) recognize 
alpha (2, 6) linked sialic acid. Glycans attached to aspargine 194 of these HAs prevent 
their binding to alpha (2,3) linked sialic acid chains. However when influenza B viruses 
are propagated in chicken eggs, the HAs lose the glycosylation sites at residues 194-196 
 9 
leading to changes in receptor binding properties as well as antigenicity (Gambaryan, 
Robertson et al. 1999).   
 
1.3.2 Virus un-coating and nuclear import 
 
After receptor attachment, the virus is endocytosed into the cells and is trafficked to 
an acidic endosomal vesicle. HA now has a second function, which is to bring about the 
fusion of the viral envelope with the endosomal envelope. This function is achieved by 
the conformational change of HA induced by the low pH. At this pH, the HA1 molecule 
remains mostly unaltered; however, the HA2 undergoes a folding event that exposes a 
previously buried ‘fusion peptide’ (Carr and Kim 1994), (Hernandez, Hoffman et al. 
1996). The fusion peptide can intercalate into bilipid membranes, bringing about the 
fusion of the endosomal and viral envelopes, thus releasing the viral RNPs into the 
cytoplasm of the infected cell, from where they are imported into the nucleus (Whittaker 
2001). 
Another role of the low pH compartment is to facilitate the un-coating of the viral 
RNP complex from the encapsulating M1 protein. The M2 protein of influenza A virus is 
an ion channel protein (Pinto, Holsinger et al. 1992) that is highly specific for the 
conductance of protons (reviewed in (Pinto and Lamb 2006), (Lamb and Krug 2001), 
(Lamb Holsinger 1994), (Hay 1992) ). In the acidic endosomal vesicle, the passage of 
protons from outside to inside of the virion by M2 lowers the pH inside the virion, 
thereby disrupting the interaction between M1 and the underlying RNP complex (Lamb 
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Holsinger 1994), (Hay 1992). M2 is a type III integral membrane protein and in its native 
state, is a homo-tetramer (Sugrue and Hay 1991). The trans-membrane domains of the 
four monomers form the channel of the pore that conducts the protons.  In the absence of 
un-coating of M1 mediated by M2, the RNP complex is too big to pass through the 
nuclear pore. The essential function of M2 is underscored by the fact that it is the target 
of an antiviral drug called amantadine. Influenza B virus also requires an essential low 
pH step in its life cycle and has an analogous ion channel protein called BM2 encoded by 
RNA segment 7.  Like M2, BM2 is a type III, oligomeric (Balannik, Lamb et al. 2008), 
trans-membrane protein and has proton specific channel activity (Mould, Paterson et al. 
2003). BM2 is also essential for proper replication of influenza B virus (Hatta, Goto et al. 
2004). Another influenza B virus protein, the NB, was initially postulated to be analogous 
to influenza A virus M2. However, while NB is also incorporated into the viral envelope 
as a small integral membrane protein (Betakova, Nermut et al. 1996), and similar in size 
to M2, its ion channel activity has not been conclusively proven, neither is it essential for 
the virus replication (Hatta and Kawaoka 2003). The exact function of NB is still not 
clearly understood. 
Once the RNP complex has been uncoated of M1, they are then imported into the 
nucleus through the nuclear pore complex. All the proteins in the RNP, namely, NP, PB1, 
PB2 and PA, contain nuclear localization signals (NLS) (O'Neill, Jaskunas et al. 1995), 
(Nieto, de la Luna et al. 1994), (Akkina, Chambers et al. 1987), (Jones, Reay et al. 1986), 
reviewed in (Whittaker and Helenius 1998). 
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1.3.3 Viral transcription and replication 
 
Influenza virus is unique among other negative sense segmented RNA viruses in that 
its replication takes place inside the nucleus rather than the cytoplasm. The viral RNA 
molecules are associated with the polymerase complex and the nucleocapsid protein 
(NP). Most of our understanding about the replication mechanisms of the polymerase 
have come from studies on influenza A virus polymerase. 
The viral polymerase is an RNA dependent RNA polymerase and is a hetero-trimer of 
three subunits: PB1, PB2 and PA. PB1 is encoded by viral RNA segment 2, PB2 by RNA 
segment 1 and PA by RNA segment 3. The polymerase forms a complex in a linear 
fashion. PA binds the N terminus of PB1 through an extensive interaction of its C 
terminus and the C terminus of PB1 binds the N terminus of PB2 (Guu, Dong et al. 2008) 
(Gonzalez, Zurcher et al. 1996), (Zurcher, de la Luna et al. 1996), (Ohtsu, Honda et al. 
2002), (Toyoda, Adyshev et al. 1996).  Influenza polymerase is involved in two 
important reactions in the viral life cycle: transcription and replication.  
Transcription:  
Transcription involves the synthesis of messenger RNAs (mRNAs) from the 
negative sense virion RNA (vRNA) as a template.  The viral mRNAs are similar in 
structure to the cellular mRNAs in that they are 5’ capped and 3’ poly-adenylated. The 
cap for the viral mRNA is obtained from the cellular mRNAs by a unique mechanism 
called ‘cap snatching’ (figure 1.4).  In this reaction, the conserved 13 nucleotides at the 5’ 
end of the vRNA binds to a site on the PB1 subunit, which activates the cap binding site 
on the PB2 and the endonuclease activity on PA subunits (Li, Rao et al. 2001), (Rao, 
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Yuan et al. 2003), (Yuan, Bartlam et al. 2009), (Dias, Bouvier et al. 2009). The 
endonuclease cleavage of the cellular mRNAs release capped structures that are 10-13 
nucleotides in length which then serve as primers for mRNA synthesis. Although the 3P 
complex ‘snatches’ the cap from host mRNAs, the viral messages are saved from the 
same fate by the polymerase complex. By binding a conserved sequence in all viral 
mRNAs immediately downstream of the cap, a cap binding activity of the polymerase is 
activated whereby the caps are protected from cleavage (Shih and Krug 1996). The 
conserved 12 nucleotides at the 3’ end of the vRNAs bind PB1 and serve as templates for 
mRNA synthesis.  The viral mRNAs are elongated until the polymerase reaches a stretch 
of uridines, around 15 to 22 nucleotides from the 5’ ends of the vRNA. At this stretch, the 
elongation terminates and a poly [A] segment is added to the mRNAs by reiterative 
copying of the stretch of the ‘U’ residues, by the viral polymerase.  The mechanism by 
which the viral polymerase itself is responsible for the addition of the poly [A] tail to the 
viral mRNAs is important because of the functions of the viral NS1A protein, which 
inhibits 3’ end processing of cellular mRNAs (reviewed in  (Chen and Krug 2000)). 
Replication: 
The replication reaction is carried out in two steps: first, the vRNA is transcribed 
into full length positive sense complimentary RNA (cRNA). The cRNA is then 
transcribed to give rise to full length negative sense vRNA.  Unlike transcription, 
replication neither depends on a primer for initiation nor is terminated at the stretch of 
uridines.   The NP protein is very crucial for the replication reaction (Shapiro and Krug 






Figure 1.4  ‘Cap snatching’ mechanism of influenza A polymerase. A.Influenza A 
polymerase contains an intrinsic endonuclease activity which cleaves 
cellular mRNAs approximately 10-13 nucleotides downstream of 5’ end of 
the RNA. This releases the cap that is then used as primer for transcription 
of viral messages. B. During initiation, a G is added at the 3’ end of the cap 
structure after which elongation (C) proceeds with the vRNA as template. 





RNA segment 5 of influenza virus and coats the viral RNA at intervals of 24 nucleotides, 
thereby covering the entire vRNA. NP is important for ‘anti-termination’, which prevents 
the polymerase from terminating at the poly uridine stretch and hence enabling it to 
transcribe a full length cRNA (Beaton and Krug 1986). NP is also important to mediate 
the switch from transcription to replication of the polymerase. The RNA binding activity 
of NP is not required for this switch; rather it has been postulated that the direct binding 
of NP to the polymerase subunits might be responsible for  the  ‘re-modeling’ of the 
polymerase, so that it switches to replication (Newcomb, Kuo et al. 2009).  
1.3.4 Export of viral RNPs 
 
The newly synthesized vRNPs must next be exported from the nucleus into the 
cytoplasm before assembly and budding. The viral proteins necessary for export are M1 
and the non structural protein 2 (NS2), also called nuclear export protein (NEP) (O'Neill, 
Talon et al. 1998). NS2 is encoded from a spliced message of RNA segment 8 of 
influenza viruses A and B and segment 7 of influenza Virus C.  NS2 binds to M1, and 
export is mediated as a vRNP-M1-NS2 complex through the nuclear pore. For efficient 
export, there is usually a ternary complex formed between the export substrate, a cellular 
export factor (CRM1 in case of influenza virus) and Ran-GTP (reviewed in (Boulo, 
Akarsu et al. 2007)). The nuclear export sequence (NES) on NS2 is essential for the 
ternary complex formation. 
1.3.5 Assembly and Budding 
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Proper packaging of influenza virus involves the assembly of the eight vRNP 
complexes contained within the viral envelope. Several recent reports have identified 
sequences at the 5’ and 3’ non coding regions as well as some coding sequences of each 
segment that is important in proper packaging of the virus (de Wit, Spronken et al. 2006), 
(Dos Santos Afonso, Escriou et al. 2005), (Fujii, Fujii et al. 2005), (Fujii, Goto et al. 
2003), (Liang, Huang et al. 2008), (Marsh, Hatami et al. 2007), (Ozawa, Maeda et al. 
2009). The integral membrane proteins, HA, NA, (B/C) M2 and NB are synthesized on 
membrane bound ribosomes and are transported through the endoplasmic reticulum (ER). 
HA and NA lack the terminal sialic acid on their carbohydrate chains, because of the 
action of NA, which catalyzes the cleavage of the terminal sialic acid residues on the 
glycol-proteins. Assembly and budding of the virus takes place at specialized regions of 
the plasma membrane known as ‘lipid rafts’, which are enriched in the viral glycoproteins 
(Scheiffele, Rietveld et al. 1999). The cytoplasmic tails of HA, NA and M2 are crucial in 
proper assembly of the virus, as they interact with M1, which in turn coats the vRNP 
forming connections with it. It was recently proved that M1 is not the major driving force 
for production of virus like particles (VLPs) (Chen, Leser et al. 2007). This is in contrast 
to several enveloped viruses whose major structural proteins contain a ‘late domain’ and 
whose expression alone can drive viral packaging and budding (Bieniasz 2006). At 
present, host factors involved in influenza virus budding are uncharacterized.  






Figure 1.5  Non structural protein 1 of influenza A and B viruses. A Schematic 
representation of NS1A (A) and NS1B (B) showing the N terminal RNA 
binding domain (red) and C terminal ‘effector domain’ (blue). Indicated are 









The segment 8 of influenza A and B viruses and Segment 7 of influenza C virus encodes 
two proteins, named non structural proteins 1 and 2 (NS1 and NS2/NEP).  NS1 is 
encoded by the un-spliced mRNA while the mRNA for NS2 is a spliced version. NS2 
functions in nuclear export of the vRNPs (section 1.3.4). Out of all the influenza viral 
proteins, NS1 and PB2-F2 (of influenza A virus) are expressed exclusively in the infected 
cell and are absent from the virion. NS1 is a multi-functional protein and has been found 
to play important roles in viral replication (by regulating polymerase function) (Min, Li et 
al. 2007), (Falcon, Marion et al. 2004), (Shimizu, Handa et al. 1994), (Scholtissek and 
Spring 1982) as well as suppressing host innate immune response against the virus 
(reviewed in (Krug, Yuan et al. 2003), (Hale, Randall et al. 2008)). The critical 
importance of NS1 is highlighted by the phenotype of recombinant influenza A and B 
viruses that lack the entire NS1 gene. These viruses are extremely attenuated. While the 
A/delNS1 virus can be rescued in IFN deficient systems like Vero cells (Garcia-Sastre, 
Egorov et al. 1998), B/delNS1 virus is highly attenuated both in interferon sufficient and 
deficient cells (Dauber, Heins et al. 2004). The NS1 proteins of influenza A and B viruses 
(henceforth referred to as NS1A and NS1B respectively) share similarities in structure 
and function (Yin, Khan et al. 2007). However the proteins share less than 20% sequence 
identity, which lead to unique functions for both. These differences in turn highlight 
differences in viral strategies for combating host defense.  
1.4.1 Structure and function of the RNA binding domain of NS1A and NS1B 






Figure 1.6    Structure of the dsRNA binding domains of NS1A and NS1B. A.Overlap 
of the RNA binding domains of NS1A (tan) and NS1B (blue). NS1B 
contains a longer loop (red) between helices 2 and 3. B. Dimer of 1-104 
amino acids of NS1B with residues important in dsRNA binding (R50 and 
R53) and those important in ISG15 binding (V87, M91 and F100) 
highlighted. Red represents residues on one monomer and green represents 
residues on the other monomer. RNA binding groove of NS1A (C) and 
NS1B (D) with residues in red representing those showing minimum to no 
variation. Adapted from (Yin, Khan et al. 2007).  
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characterized by an N terminal RNA binding domain and C terminal ‘effector’ domain 
(figure 1.5). Both proteins are homo-dimers with the N terminal and C terminal both 
contributing to dimerization. The structure of the RNA binding domain has been resolved 
by NMR and X ray crystallography for both NS1A and NS1B and found to be highly 
similar (figure 1.6), (Chien, Tejero et al. 1997), (Liu, Lynch et al. 1997; Yin, Khan et al. 
2007), (Cheng, Wong et al. 2009). This domain, which is made up of 1-73 amino acids of 
NS1A and 1-93 amino acids of NS1B, has a novel six alpha-helical fold formed by a 
dimer of NS1 with the RNA binding groove made up of positively charged basic residues 
present in helix 1 and helix 2 of each monomer. The RNA binding domain binds dsRNA 
in a sequence independent manner, but does not bind dsDNA or RNA/DNA hybrids. The 
interaction however is weak in comparison to other dsRNA binding proteins and has a 
dissociation constant (kd) of ~1uM (Chien, Xu et al. 2004). Several residues along the 
RNA binding groove have been shown to form contacts with the RNA (Yin, Khan et al. 
2007); however the critical residue in NS1A is the arginine at position 38 (R38); the 
mutation of which to alanine completely abrogates dsRNA binding in in vitro gel shift 
assays (Wang, Riedel et al. 1999). By using a recombinant influenza A virus which 
encoded an NS1 protein with an R38A mutation, the function of dsRNA binding of 
NS1A in infected cells is to inhibit the 2’5’ oligo adenylate synthetase (2’-5’ OAS)-
RNaseL anti-viral pathway.  
There is some controversy regarding the role of the dsRNA binding domain of 
NS1B. Since the structure of this domain as well as the substrate specificity of NS1B is 
highly similar to that of NS1A (Wang and Krug 1996), (Yin, Khan et al. 2007), it is 
reasonable to propose that the function of dsRNA binding in NS1B serves the same 
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purpose as that of NS1A. However, a group of researchers proposed that the function of 
dsRNA binding of NS1B was to inhibit the activation of protein kinase R (PKR)  
(Dauber, Schneider et al. 2006). PKR is an interferon induced, dsRNA activated protein 
kinase, which is involved in shut down of protein synthesis and apoptosis of the infected 
cell (reviewed in (Sadler and Williams 2007)). However, the residues in NS1B that were 
mutated to abolish RNA binding also mis-localize the protein to the cytoplasm 
(Schneider, Dauber et al. 2009), since this region also forms the sole nuclear localization 
sequence for NS1B.  The absence of a second NLS in NS1B (like in some NS1A 
proteins) has proved an obstacle to determining the precise role of dsRNA binding of 
NS1B in infected cells.  Also, unlike NS1A which directly binds PKR (Li, Min et al. 
2006), the binding of NS1B to PKR is RNA mediated since a R50AR53A double mutant 
of NS1B that disrupts dsRNA binding (Yuan, Aramini et al. 2002), (chapter 3) also has 
dramatically reduced PKR binding capacity in co-immunoprecipitation experiments 
(Sridharan and Krug, unpublished data). However, the R50AR53A mutant NS1B protein 
is mis-localized to the cytoplasm (chapter 3) and it is not known if NS1B binds to PKR in 
nucleus or cytoplasm. Therefore, the function of the dsRNA binding domain of NS1B in 
infected cells is yet to be determined. 
1.4.2 Structure and function of the ‘effector’ domain of NS1A 
 
The C terminus of NS1A constitutes the ‘effector’ domain and has been shown to 
be the binding site of several host factors, like the 30kd subunit of the cellular cleavage 
and poly-adenylation specificity factor (CPSF), poly (A) binding protein II (PABII), PKR 
and PI3-kinase (PI3K). CPSF30 and PABII are involved in the 3’ end processing of 
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cellular pre-mRNAs that lead to the addition of the poly (A) tail. 3’ end processing is a 
crucial step in the maturation of mRNAs since the inhibition of this step results in 
unstable messages whose nuclear export is inhibited. NS1A inhibits the activity of 
CPSF30 and PABII, by binding these proteins (Nemeroff, Barabino et al. 1998), (Chen, 
Li et al. 1999), thereby preventing the translation of host anti-viral messages (Noah, Twu 
et al. 2003). The interaction between NS1A and CPSF30 has been well characterized by 
both structural studies as well as mutational analyses. A crystal structure of the complex 
of the effector domain of NS1A (amino acids 85-215) and the F2-F3 Zinc finger fragment 
of CPSF30, which is sufficient to bind NS1A (Twu, Noah et al. 2006), shows that a dimer 
of NS1A binds two molecules of F2-F3 (Das, Ma et al. 2008). A single point mutation, 
G184R of NS1A is sufficient to abolish CPSF30 binding and a recombinant influenza A 
virus whose NS1 contains this mutation is highly attenuated and cannot inhibit the 
synthesis of IFN message in the infected cell (Das, Ma et al. 2008). Besides G184, two 
other amino acids outside the binding pocket, F103 and M106, serve to stabilize the 
NS1A-CPSF30 complex (Twu, Kuo et al. 2007), (Das, Ma et al. 2008), as does the viral 
polymerase complex which is also present in this complex (Kuo and Krug 2009). The 
multiple levels at which the NS1A-CPSF30 complex is stabilized underscores its 
importance in the viral strategy of countering the host antiviral response. The viral 
messages themselves escape the fate of inhibition of 3’ end processing that is mediated 
by NS1A, since their 3’ end processing and poly (A) addition is carried out by iterative 
copying by the viral polymerase itself and does not depend upon the host machinery 
(Luo, Luytjes et al. 1991), (Poon, Pritlove et al. 1999), (Robertson, Schubert et al. 1981).  
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Besides CPSF30, another NS1A interacting host protein is PKR. It has been long 
observed that PKR activation is inhibited in influenza A virus infected cells and that this 
inhibition is at least partly mediated by the NS1A protein (Bergmann, Garcia-Sastre et al. 
2000), (Hatada, Saito et al. 1999). Recently, it was shown that the mechanism of 
inhibition by NS1A was by its direct binding to PKR through amino acids 123 and 124 of 
NS1A, and not due to sequestration of dsRNA away from PKR (Li, Min et al. 2006), 
(Min, Li et al. 2007).  
Recently many studies have shown that NS1A interacts with the p85β but not the 
p85α subunit of phospatidyl inositol 3 kinase (PI3K) through the amino acids 164-167 as 
well as amino acids 141 and 142 in NS1A (Hale, Jackson et al. 2006; Shin, Li et al. 2007; 
Shin, Liu et al. 2007; Li, Anderson et al. 2008); (Hale, Batty et al. 2008).  Such an 
interaction activates PI3K, leading to the phosphorylation and activation of downstream 
kinase Akt.  Studies have also shown that NS1 of avian but not human influenza viruses 
bind to Crk and/or CrkL via amino acids 212 to 216 (Heikkinen, Kazlauskas et al. 2008), 
thereby increasing the phosphorylation of Akt. The PI3K-Akt pathway suppresses virus-
induced apoptosis, thereby allowing replication of the virus during early times post 
infection (reviewed in (Ehrhardt and Ludwig 2009)). 
1.4.3 Functions of the ‘effector’ domain of NS1B 
 
Unlike NS1A, NS1B neither binds CPSF30 and inhibits the maturation of host 
messages (Wang and Krug 1996), nor activates the PI3K-Akt pathway (Ehrhardt, Wolff 
et al. 2007). Much less is known about the functions of the ‘effector’ domain of NS1B, 
because of the lack of knowledge about interacting partners. One characterized 
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interaction is between NS1B and the cellular protein, the interferon stimulated gene 
product 15 (ISG15) (Yuan and Krug 2001). ISG15 is an interferon induced ‘ubiquitin-
like’ protein which is discussed in depth in section 1.7. NS1A does not bind ISG15; 
indeed, in influenza A virus infected cells, little or no ISG15 is made (Kim, Latham et al. 
2002) since NS1A blocks 3’ end processing of host cell mRNAs. Previous studies in our 
laboratory showed that the binding site of ISG15 on NS1B is contained within the N 
terminal 103 amino acids of NS1B (Yuan and Krug 2001). The binding site has 
contributions from both the dsRNA binding domain (amino acids 1-93) as well as the ten 
amino acids after the dsRNA binding domain (amino acids 93-103), since neither the 
dsRNA binding alone nor a NS1B mutant that lacks the dsRNA binding domain but 
contains amino acids 93-103 is sufficient to bind ISG15. Initially, the amino acids present 
in loop1 (loop between alpha helices 1 and 2) of NS1B were thought to mediate this 
interaction (Yuan, Aramini et al. 2002). However, the structure of the dsRNA binding 
domain of NS1B that was subsequently resolved (Yin, Khan et al. 2007) indicated that 
these mutations would disrupt the protein structure and was not the true binding site.  In 
the current study (chapter 2), the major binding site for ISG15 on NS1B has been 
determined and found to involve the third alpha helix of dsRNA binding domain of 
NS1B. Further, a triple point mutant of NS1B was characterized that disrupts ISG15 
interaction but still retains other functions of NS1B like intra-nuclear localization. This 
suggests that in the triple mutant, the protein structure is mostly retained. 
NS1B, like NS1A, inhibits interferon (IFN) β production (Dauber, Heins et al. 
2004) although the mechanism of this inhibition must be different from that of NS1A 
since NS1B does not bind CPSF30. The C terminal effector domain of NS1B is 
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responsible for this inhibition, as recombinant viruses that contain a truncated NS1B 
protein of 1-104 amino acids induce dramatically higher IFN β (Donelan, Dauber et al. 
2004). Furthermore, unpublished results from our laboratory have shown that the C 
terminus of NS1B inhibits the activation of the transcription factor, interferon response 
factor 3 (IRF-3), which induces the transcription of IFN β message. In contrast, several 
influenza A viruses like Udorn/72 and WSN activate IRF-3 (Kim, Latham et al. 2002), 
(Das, Ma et al. 2008). It remains to be determined if the inhibition of IRF-3 activation by 
NS1B accounts for the full inhibition of IFN production. 
NS1B shows unique intra-nuclear localization to splicing compartments known as 
SC35 or splicing speckles, so named for the characteristic accumulation of the splicing 
factor, SC35 (chapter 3) and (Schneider, Dauber et al. 2009). However, the function for 
this localization is not understood. SC35 speckles and NS1B’s localization to these 
structures are discussed in detail in section 1.8. NS1B also possesses as yet 
uncharacterized functions that are not dependent on the interferon response of the cell, 
since a recombinant virus that lacks the entire NS1 gene is attenuated in both interferon 
competent MDCK cells as well as in interferon deficient Vero cells (Dauber, Heins et al. 
2004). Further studies are necessary to fully understand the role(s) of NS1B in virus 
infection.  
1.5 PREVENTION AND TREATMENT OF INFLUENZA  
 
The most effective protection against influenza is vaccination and may include 
inactivated vaccines (TIV) or live attenuated vaccines (LAIV). The vaccine’s 
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composition is based on currently circulating strains and prediction of future strains for 
that year and usually consists of a combination of influenza A viruses and an influenza B 
virus (www.cdc.gov/flu). Vaccination must be performed on a yearly basis because of the 
variation of circulating strains of influenza between each year. Research is also being 
done on live attenuated vaccines that mutate critical functions of certain viral proteins 
which result in a highly attenuated virus (Watanabe, Watanabe et al. 2009), (Wressnigg, 
Shurygina et al. 2009), (Steel, Lowen et al. 2009).  
There also exist anti-viral therapies for influenza, which target the action of 
various viral proteins. Amantadine (trade name Symmetrel, generic version amantadine 
hydrochloride) and Rimantadine (trade name Flumadine, generic version rimantadine 
hydrochloride) are two related anti viral drugs which have two modes of action based on 
the concentration. Their main mode of action is by inhibiting influenza A viral M2 ion 
channel protein, which is essential for the virus to un-coat and disassemble after 
endocytosis. At later stages of the viral infection, these drugs act on the HA molecule 
(primarily the H7 subtype) to induce a premature pH induced conformational change in 
HA (summarized from (Lamb and Krug 2001)). Recently, many influenza viruses have 
developed resistance to Amantadine and Rimantadine (2006 CDC Health alert 
http://www.cdc.gov/flu/han011406.htm). Another newer set of anti viral drugs, 
Zamamivir (Relenza®) and Oseltamivir (Tamiflu®), act on the NA protein. NA binds 
sialic acid, cleaving it from viral and cellular glycoproteins, thus facilitating viral release 
from the cell. Zanamivir is a sialic acid analog and inhibits the NA of both influenza A 
and B viruses. Oseltamivir is an orally administered pro-drug of Zamamivir. Current 
research is also focusing on the potential use of other viral proteins as targets for drugs, 
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like NS1 and NP proteins. The resolving of crystal structures of these proteins (Yin, Khan 
et al. 2007), (Bornholdt and Prasad 2006), (Bornholdt and Prasad 2008), (Ye, Krug et al. 
2006), along with great advances in the understanding of their functions have identified 
them to be good targets for the development of molecules that can inhibit their functions. 
1.6 THE HOST RESPONSE TO VIRAL INFECTION 
 
 
When a virus infects a host cell, the cell mounts a defense mechanism that 
ultimately results in what is known as the ‘anti-viral state’ of the cell. The induction of 
this state involves hundreds of genes whose action inhibit various stages of viral life 
cycle like blocking protein translation, preventing virus budding, induction of apoptosis 
etc. Some of the most important mediators of the host antiviral mechanism are cytokines 
known as interferons (IFNs). The host response to viral infection takes place in a biphasic 
pattern; an immediate early response that is independent of IFN and a second late 
response that is mediated by IFN (reviewed in (Haller, Kochs et al. 2006)). Figure 1.7 
describes an overview of the biphasic pattern of host anti-viral response. 
 
1.6.1 Early interferon independent anti-viral response 
The immediate early IFN independent response does not require viral protein 
synthesis and results in the induction of several antiviral genes including IFN β (reviewed 
in (Krug, Yuan et al. 2003), (Haller, Kochs et al. 2006)).  This phase is dependent upon 
the activation of a transcription factor called interferon regulated factor 3 (IRF-3). In 
recent years, many of the steps in the pathway leading to the activation of IRF-3 have 
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been described. Upon viral infection of host cell, pathogen associated molecular patterns 
(PAMPs) like viral genomic ssRNA or dsRNA replication intermediates are recognized 
by either membrane bound or cellular pattern recognition receptors (PRRs). These two 
classes of receptors signal through the two distinct pathways described below to activate 
IRF-3 and subsequently induce transcription of IFN β message (reviewed in (Meylan and 
Tschopp 2006)).  
Membrane bound receptors include the Toll like receptors (TLRs) 3,7 and 8 
which are present on the membranes of intracellular organelles (reviewed in (Honda and 
Taniguchi 2006), (Meylan and Tschopp 2006)). TLR 7 and 8 recognize ssRNA, TLR 3 
recognizes dsRNA and TLR 9 recognizes non methylated CpG DNA motifs 
(Alexopoulou, Holt et al. 2001), (Diebold, Kaisho et al. 2004), (Heil, Hemmi et al. 2004), 
(Hemmi, Takeuchi et al. 2000), (Lund, Alexopoulou et al. 2004). Activation of TLRs is 
achieved by the phosphorylation of their cytoplasmic domains which then signal through 
various TIR domain containing adaptor proteins like MyD88 or Trif. MyD88 forms a 
complex with TRAF6 and IRF-7, leading to the activation of IRF-7. Trif recruits the 
kinase TBK-1 which phosphorylates and activates IRF-3 and IRF-7, ultimately leading to 
the induction of IFN β message. Trif also leads to activation of the transcription factor 
NFκB also by recruiting TRAF6 or TRAF3. The TLR pathway for inducing IFN β occurs 
predominantly in the plamacytoid Dendritic Cells (pDCs), which are specialized cells for 
producing IFN (reviewed in (Honda and Taniguchi 2006), (Meylan and Tschopp 2006)). 
Cellular receptors for viral nucleic acids like RIG-I and MDA-5 are activated by 
dsRNA, ssRNA or Poly I:C. PolyI:C activates MDA-5 (Kato, Takeuchi et al. 2006), 





Figure 1.7   Biphasic pattern of anti-viral response. Upon virus infection, signaling by 
pattern recognition receptors like RIG-I or TLRs result in the induction of 
IFN β message. IFN β, in an autocrine or paracrine manner, signals through 
JAK-STAT pathway to induce the full range of IFN induced proteins. 









RIG-I but not MDA-5 in vitro (Hornung, Ellegast et al. 2006), (Pichlmair, Schulz et al. 
2006). Other ligands identified for RIG-I include RNA bearing 5’ triphosphate (Hornung, 
Ellegast et al. 2006), (Pichlmair, Schulz et al. 2006) as well as the poly U/UC part of the 
3’UTR of Hepatitis C Virus (HCV) (Saito, Owen et al. 2008).  Similarly, influenza A 
virus infection is able to induce RIG-I activation (Siren, Imaizumi et al. 2006), (Kato, 
Takeuchi et al. 2006), (Loo, Fornek et al. 2008); however the exact motifs in the viral 
genome have not yet been discovered. Once activated, RIG-I and MDA-5 signal through 
the adapter protein variously called MAVS, Cardiff, VISA or IPS-1 (Meylan, Curran et 
al. 2005; Xu, Wang et al. 2005), (Kawai, Takahashi et al. 2005). Ultimately, this pathway 
leads to the activation of IRF-3. Different RNA viruses activate IFN β production 
through either RIG-I or MDA-5 (Kato, Takeuchi et al. 2006), (Loo, Fornek et al. 2008), 
(Gitlin, Barchet et al. 2006) while some viruses like orthoreovirus, dengue virus and west 
nile virus signal through both.   
IRF-3 is a 55 kDa constitutively expressed protein of the IRF family which to date 
has 9 members (IRFs 1-9). Signaling through TLRs or RIG-I/MDA5 leads to 
phosphorylation of IRF-3 in its C terminal domain by the kinases IKKε and TBK-1, 
resulting in dimerization and activation (reviewed in (Hiscott 2007), (Honda and 
Taniguchi 2006)). Dimerized IRF-3 translocates to the nucleus where it binds 
transcriptional co-activators p300 and CREB binding protein (CBP) leading to a virus 
activated factor (VAF), which binds the promoter element interferon stimulated response 
element (ISRE) of a subset of ISRE containing genes to induce their transcription 
(reviewed in (Hiscott 2007), (Honda and Taniguchi 2006)). In a microarray study to 
identify genes that are directly induced by IRF-3, a subset of interferon stimulated genes 
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(ISGs) like p54, p56, ISG60 were found to be strongly induced and others like ISG15, 
2’5’OAS were modestly induced (Grandvaux, Servant et al. 2002). While IRF-3 alone 
can activate the above mentioned genes, efficient transcription of IFN β message 
involves the formation of an ‘enhansosome’ comprising the transcription factors IRF-3, 
NFκB, and ATF-2/c-Jun (Du and Maniatis 1992), (Du, Thanos et al. 1993), (Fujita, 
Miyamoto et al. 1989), (Suhara, Yoneyama et al. 2002). The importance of IRF-3 in the 
induction of IFN was demonstrated by IRF-3
-/- 
mice which produced much less IFN when 
infected with encephalomyocarditis virus as compared to wild type mice infected with the 
same virus (Sato, Suemori et al. 2000). Many influenza A viruses with the exception of 
A/PR8 virus activate IRF-3 (Kim, Latham et al. 2002), (Das, Ma et al. 2008); however 
although it was initially shown that influenza B virus activates IRF-3, subsequent 
experiments both by our lab and others (Donelan, Dauber et al. 2004) have indicated that 
IRF-3 is inhibited in influenza B virus infection and that this inhibition is mediated by the 
NS1B protein. The exact mechanism of this inhibition is currently being worked out. 
The other important member of the IRF family required for the full induction of 
interferon response is IRF-7. IRF-7 is considered to be the master regulator because in 
IRF-7
-/- 
mice, the induction of IFN α is completely inhibited while that of IFN β is 
greatly reduced (Sato, Suemori et al. 2000). While IRF-3 is a constitutive protein, IRF-7 
is virus and dsRNA inducible, except in the case of pDCs, where it is constitutively 
expressed. Like IRF-3, IRF-7 is activated by phosphorylation in its C terminus. A hetero-
dimer of IRF-3 and IRF-7 leads to the full activation of IFN α and all subtypes of IFN β 
gene. While IRF3 is responsible for the early expression of IFN, IRF7 controls a second 
late induction of IFN (reviewed in (Hiscott 2007)). 
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1.6.2 Anti-viral response mediated by the interferon system 
Interferons (IFNs) are cytokines that were first discovered during influenza virus 
infection. Interferons play a crucial role in the innate immunity against viruses and other 
intracellular pathogens. The importance of the interferon system in innate antiviral 
response of the host is apparent by the phenotype of knockout mice lacking various forms 
of IFN (Huang, Hendriks et al. 1993), (Muller, Steinhoff et al. 1994), (Hwang, Hertzog et 
al. 1995) . These mice are unable to effectively counter infection by a wide range of 
viruses despite having a functional adaptive immune system. 
 
Classification of Interferons 
There are three main classes of IFNs, classified on the basis of gene sequence, 
chromosome location and receptor specificity (Pestka, Krause et al. 2004). Type I IFNs 
consist of fourteen different IFNα, one IFN β, one IFN ω, one IFN Є and one IFN κ 
proteins. Type I IFNs are produced by all cell types and are recognized by a ubiquitously 
expressed IFN α Receptor (IFNAR), composed of two chains, IFNAR1 and IFNAR2. 
Type II IFNs consist of only one IFN, IFN γ.  IFN γ is produced only by cells of the 
immune system like monocytes and lymphocytes and is recognized by the ubiquitously 
expressed IFN Gamma Receptor (IFNGR), composed of IFNGR1 and IFNGR2 chains. 
Type III IFNs were recently discovered (Sheppard, Kindsvogel et al. 2003), (Kotenko, 
Gallagher et al. 2003) and consist of three types: IFN λ1, IFN λ2 and IFN λ3 and are 
recognized by a receptor comprised of two chains: IFN λR1 which is expressed in 
specific cell types and the ubiquitously expressed IL-10Rβ.  
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Signaling by interferons 
All three types of IFNs follow a similar pattern of signaling (reviewed in 
(Platanias 2005), (Stark, Kerr et al. 1998)). The binding of ligand to receptor triggers a 
complex signal transduction pathway involving the receptor associated janus activated 
kinases (JAKs). Specific JAKs are auto phosphorylated and activated upon engagement 
of the receptor. The activated JAKs then phosporylate and activate specific latent signal 
transducer and activator of transcription (STAT) molecules in the cytoplasm. The 
phosphorylated STATs translocate to the nucleus where they form a complex with other 
STAT molecules and/or other transactivators to bind to specific elements in the 
promoters of interferon stimulated genes (ISGs) leading to the transcription of hundreds 
of genes the products, which set up an ‘anti-viral state’. Specific JAKs and STATs that 
are activated by each type of IFN afford a level of specificity as well as complexity. Type 
I IFNs activate the JAKs, Tyk1 and JAK1 and STAT1, 2, 3 and 5. While all type I IFNs 
activate these STATs, IFN α can also sometimes activate STAT4 and STAT5, but these 
are restricted to certain cell types. The most important transcription activation complex 
induced by Type I IFNs is the interferon stimulated gene factor 3 (ISGF3) complex. 
ISGF3 consists of a complex of STAT1, STAT2 and IRF-9. This complex binds to a 
specific sequence in the promoter of target genes called interferon stimulated response 
element (ISRE), inducing the transcription of the target genes. IFN γ activates JAK1 and 
JAK2, which in turn activate STAT1 resulting in the formation of STAT1-STAT1 
homodimers which translocate to the nucleus and bind to promoter elements called 
gamma activated sequences (GAS) to induce the transcription of  target genes. Some 
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genes have only ISRE or GAS while others have both elements; therefore different 
combinations of STATs can mediate different responses (reviewed in (Platanias 2005), 
(Stark, Kerr et al. 1998)). 
 
Interferon induced proteins 
Using microarray analysis of samples from both human and murine cells treated 
with IFN α, IFN β or IFN γ, over 300 IFN stimulated genes were identified (de Veer, 
Holko et al. 2001), which expanded a previous study identifying 122 proteins (Der, Zhou 
et al. 1998). The responsive genes fall into many functional categories, the largest 
category being host defense or signaling. Some of the IFN induced proteins involved in 
host defense (PKR, 2’5’ Oligo A Synthetase, Mx proteins) have been very well 
characterized in terms of their mechanism of action and many viruses have strategies for 
inhibiting or evading them (Levy and Garcia-Sastre 2001), (Haller, Kochs et al. 2006). 
ISG15 is an ubiquitin-like protein that is induced by type I interferons and also by IRF-3. 




ISG15 belongs to a class of proteins called the ‘ubiquitin-like’ proteins, which 
includes SUMO, NEDD8 and FAT10. ISG15 is expressed only in vertebrates and is 
highly induced upon a variety of stress signals like viral or bacterial infection, interferon 
treatment, and retinoic acid treatment (Yuan and Krug 2001), (Lenschow, Lai et al. 
2007), (Vargas-Inchaustegui, Xin et al. 2008), (Pitha-Rowe, Hassel et al. 2004).  
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1.7.1 Enzymatic cascade and targets of ISG15 conjugation 
ISG15 uses a similar enzymatic cascade as ubiquitin to conjugate to target 
proteins. The cascade for ubiquitin is hierarchical, involving (for vertebrates and sea 
urchin) two activating enzymes (E1), 10-20 conjugating enzymes (E2s), and hundreds of 
ligating enzymes (E3s). In an ATP dependent step, E1 activates ubiquitin by forming a 
thioester bond between a thiol group in its active site and the carboxyl group of the C 
terminal glycine of ubiquitin.  Activated ubiquitin is then transfered to the E2 enzyme, 
which also forms a similar thiol ester bond involving a thiol group in its active site. The 
third enzyme in the pathway is the E3. There are two forms of E3s: RING E3s act as 
scaffolding proteins, bringing the targets in contact with the E2~ubiquitin complex while 
HECT (homology to E6AP carboxy terminal) domain containing E3s are catalytically 
active and form a thioester bond with ubiquitin through a thiol group in its active site. 
Finally, ubiquitin is conjugated to target proteins by formation of an isopeptide bond 
between the carboxyl group of the C terminal glycine of ubiquitin and the amino group of 
a lysine in the target (summarized from (Pickart 2001)).  
The conjugation cascade for ISG15 is illustrated in figure 1.8. The ISG15 
activating enzyme was found to be Ube1L (Ubiquitin E1 like) (Yuan and Krug 2001). 
Ube1L is deleted in a number of small cell lung carcinoma cell lines (Kok, Hofstra et al. 
1993); (McLaughlin, Helfrich et al. 2000); (Pitha-Rowe, Hassel et al. 2004); (Pitha-
Rowe, Petty et al. 2004). This observation gave rise to the hypothesis that it might be a 
tumor suppressor; however direct evidence for its role as a tumor suppressor gene is 
lacking. Ube1L functions uniquely in the ISG15 pathway, as it cannot activate ubiquitin 
 35 
(Yuan and Krug 2001). Usually, ubiquitin-like molecules have their own unique E1 
enzyme(s) and are unable to utilize ubiqutin E1. This is the case for human and mouse 
ISG15, however, a recent study of the ISG15 from old world monkeys (owm) like 
African Green Monkey and the Rheseus Macaque showed that this ISG15 homolog is 
able to form a thio-ester intermediate with ubiquitin E1 (Pattyn, Verhee et al. 2008). The 
second enzyme in the pathway, ISG15 conjugating enzyme, was discovered to be UbcH8 
(Zhao, Beaudenon et al. 2004). siRNA knock out of UbcH8 almost completely abolishes 
ISG15 conjugation suggesting that it is the predominant E2 used in ISG15 conjugation. 
An interesting note is that Ube1L can transfer ISG15 to UbcH8 but not to another closely 
related E2, UbcH7. This specificity is mediated by structural features contained within 
the N terminal 39 amino acids of UbcH8, which Ube1L bound specifically (Durfee, 
Kelley et al. 2008). The last enzyme in the pathway, the ISG15 ligase, is Herc5, which is 
a HECT domain containing ligase (Dastur, Beaudenon et al. 2006), (Wong, Pung et al. 
2006), (Takeuchi, Inoue et al. 2006). Interestingly, knock-down of Herc5 using siRNA in 
transfection experiments markedly reduced the overall ISG15 conjugation suggesting that 
Herc5 is the predominant E3 for ISG15 and facilitates ISG15 conjugation to a large 
number of target proteins. This is unlike the ubiquitin system, where the ligase usually 
interacts with a specific target(s) and hence mediates target specificity. Herc5 perhaps 
interacts with adaptor protein(s) that in turn mediate target specificity. Unlike Herc5, 
another E3, a RING domain containing protein, estrogen-responsive finger protein (EFP), 
functions as a more specific ISG15 ligase to target the protein 14-3-3σ for ISGylation 







Figure 1.8   Mechanism of action of ISG15. See text for details. Adapted from Sadler 




of 14-3-3σ. Similar to Ube1L, UbcH8, Herc5 and ISG15, EFP is also induced by type I 
IFNs. Deconjugating enzymes play an important role in the proteolytic processing of 
precursor ubiquitin and ubiquitin-like proteins to result in the mature form. They also 
help to recycle ubiquitin and ubiquitin-like proteins by cleaving them off targets to be 
available to be conjugated to other targets (reviewed in (Wing 2003)). Ubp43 (Usp18) 
was proposed to be an ISG15 specific protease that removes ISG15 from conjugated 
proteins (Malakhov, Malakhova et al. 2002). Mice lacking Ubp43 showed elevated levels 
of ISG15 conjugates and a severe phenotype like brain injury and early death 
(Malakhova, Yan et al. 2003). However, these effects were not rescued in Ubp43/ISG15 
double knock out mice, demonstrating that the phenotype of Ubp43 
-/- 
mice is not related 
to ISG15 (Knobeloch, Utermohlen et al. 2005).  Also, if Ubp43 is the predominant ISG15 
processing enzyme, mature ISG15 and its conjugates must be absent in these mice, which 
is not the case. Therefore, it is unclear what the precise role of Ubp43 is. Like ISG15, 
Ube1L, UbcH8 and Herc5 are all IFN induced proteins. Therefore, upon IFN treatment, 
ISG15 is conjugated to a wide variety of targets. During a proteomics study of ISG15 
targets in HeLa cells, over 150 targets were discovered, which include proteins involved 
in a wide range of cellular functions (Zhao, Denison et al. 2005), (Giannakopoulos, Luo 
et al. 2005). Many of the target proteins are associated with the cytoskeleton. This is 
consistent with a previous study which found that ISG15 localized to the intermediate 
filaments (Loeb and Haas 1994). A large number of targets are involved in metabolism 
and chromatin remodeling/RNA polymerase II transcription. Many of the target proteins 
are constitutively expressed, but twelve are IFNα/β induced. Out of these twelve, nine 
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have been shown to have antiviral functions; these include P54, P56, P60, P58, RIG-1, 
STAT1, MxA, GBP-1 and PKR.   
In spite of the identification of many targets, studies on the function of ISGylation 
of individual proteins have not yielded many conclusive insights. In one study, the 
mRNA 5’ cap binding protein, 4EHP, was found to be conjugated to ISG15 (Okumura, 
Zou et al. 2007). 4EHP in Drosophila acts as an inhibitor of translation inhibitor (Cho, 
Poulin et al. 2005), presumably by competing with translation initiation factors, eIF4e 
and eIF4e3 for binding to the cap.  Conjugation of 4EHP to ISG15 led to an enhancement 
of cap binding activity of 4EHP (Okumura, Zou et al. 2007), however this enhancement 
was weak.  ISGylation also protected IRF-3 from being degraded thereby sustaining and 
enhancing the IRF-3 response (Lu, Reinert et al. 2006). However another group showed 
that ISGylation negatively regulates RIG-1 helicase (Kim, Hwang et al. 2008). Since 
RIG-1 functions upstream of IRF-3 in the same pathway to activate IRF-3, it is unclear 
why ISG15 conjugation should have the opposite effect on two proteins of the same 
pathway. Recently, cyclin D1 has been shown to be targeted by ISG15 conjugation, 
resulting in its inhibition and thus leading to cell growth suppression (Feng, Sekula et al. 
2008). Transfection of UBE1L reduces protein stability of cyclin D1, and a lysine-less 
cyclin D1 is more resistant to UBE1L, suggesting that conjugation to ISG15 is mediating 
this effect. Similar to other ‘ubiquitin-like’ modifiers, ISGylated targets constitute a very 
small (1-5%) fraction of the total target pool in a cell. This has been one of the challenges 
in attributing function of ISG15 conjugation to the target proteins; the small fraction of 
conjugated proteins would favor a gain of function rather than a loss of function model 
for target proteins. 
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1.7.2 Crystal structure of ISG15 
The crystal structure of ISG15 has been determined and is shown in figure 1.9 
(Narasimhan, Wang et al. 2005). ISG15 has two domains, each characterized by a β 
grasp fold identical to ubiquitin and separated by a hinge region. Each domain contains a 
five strand mixed β sheet intercalated by a three turn α helix and also two 310 helices that 
are characteristic of ubiquitin. The authors note that while the orientation of the two 
domains with respect to each other might represent the most stable solution structure, the 
hinge region might orient the domains differently when ISG15 interacts with other 
proteins (Narasimhan, Wang et al. 2005). In its overall organization, ISG15 is very 
similar to FAT10, which is the only other tandem domain ubiquitin like protein to be 
identified. The C terminal domain of ISG15 is responsible for forming thiol ester bonds 
with the activating enzyme UBE1L and the conjugating enzyme UBCH8 (Chang, Yan et 
al. 2008). The C terminal domain also has a characteristic terminal ‘LRLRGG’ motif that 
is conserved among ubiquitin and ubiquitin like proteins and is required for the 
conjugation to target proteins. The N terminus of ISG15 is predicted to be involved in 
increasing the number of conjugated targets, since the total number of conjugates of C 
terminus alone  is much lower than that of the full length protein (Chang, Yan et al. 
2008). Results presented in this study (chapter 2) and others’ (Chang, Yan et al. 2008) 
show that the N terminus of ISG15 is also important for binding NS1B protein of 
influenza B virus. My results (chapter 2) also indicate an important role for the hinge 
region of ISG15 in recognition of NS1B.  
 
1.7.3 ISG15 and innate immunity 
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The observation that ISG15 as well as its conjugating enzymes are all induced by 
interferon as well as the fact that some of the targets are known antiviral proteins 
activities has led to the hypothesis that one of the functions of ISG15 conjugation is in the 
innate host anti-viral response. ISG15 is a secreted protein and functions as a cytokine. It 
has been implicated in the activation of neutrophils and shown to induce IFNγ from T 
cells and NK cell proliferation (Owhashi, Taoka et al. 2003), (D'Cunha, Knight et al. 
1996), (Recht, Borden et al. 1991). It is not known at this point whether conjugation has 
any part to play in its function as a cytokine; however an intact C terminal domain 
containing the ‘LRLRGG’ motif is required for its biological activity (D'Cunha, Knight et 
al. 1996).   
Antiviral activity of ISG15 
It has been demonstrated that ISG15 has antiviral activity against specific viruses.  The 
first virus that ISG15 was shown to inhibit was Sindbis virus (Lenschow, 
Giannakopoulos et al. 2005). Recombinant Sindbis virus expressing ISG15 was shown to 
be attenuated in mice as compared to Sindbis virus expressing ISG15 that contained a 
mutation early in its reading frame. Even though the C terminal LRLRGG motif of 
ISG15 was found to be important for this protection, it is not clear if conjugation of 
ISG15 per se is required since the protective function of ISG15 was shown in IFN α/β-/- 
mice where conjugation does not occur. ISG15 
-/- 
mice are also more susceptible to 
infection by influenza A, influenza B, Herpes and Sindbis viruses (Lenschow, Lai et al. 
2007). Expression of ISG15 and its conjugates is suppressed in influenza A virus infected 
cells in tissue culture due to the viral inhibition of 3’ end processing of cellular  
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Figure 1.9   Crystal structure of ISG15. N and C terminal domains of human ISG15 









pre-mRNAs leading to their degradation (Kim, Latham et al. 2002). However, following 
infection with either influenza A or influenza B virus, wild type mice express free and 
conjugated ISG15 in the lung. Significantly more ISG15 
-/- 
mice succumbed to influenza 
A and B virus infection as compared to the control mice (Lenschow, Lai et al. 2007). 
UBE1L knock out mice showed similar sensitivity to infection with influenza B virus 
(Lai, Struckhoff et al. 2009). Studies from our laboratory have shown that ISG15 inhibits 
influenza A virus in human tissue culture (Hsiang Zhao, accepted for publication). When 
A549 or Calu-3 cells were pre-treated with IFN β before virus infection, wild type 
influenza A virus was inhibited and rescued upon siRNA knock down of ISG15 
conjugation. This rescue was at the level of viral protein synthesis, since a siRNA knock 
down of another IFN induced protein, Viperin, which inhibits influenza A virus at the 
budding stage did not affect viral protein synthesis. This is also the first report to 
conclusively show that conjugation per se is antiviral since knock out of UbcH8 alone 
(which does not deplete the free ISG15 levels) is able to rescue the virus. The mice 
studies which show that ISG15 has an antiviral activity against influenza B virus 
(Lenschow, Lai et al. 2007) was surprising to us, since it suggested that NS1B is unable 
to protect against the anti-viral activity of ISG15 in mice. Indeed, my results (chapter 2) 
show that that might be the case since NS1B is unable to bind mouse ISG15. My results 
explain why influenza B virus is rescued in mice lacking ISG15. Recently ISG15 has 
been shown to inhibit Vaccinia virus replication in vitro (Guerra, Caceres et al. 2008). 
This study implicated the viral E3 protein to be responsible for inhibiting the activity of 
ISG15 since an attenuated virus that lacks the entire E3 protein was able to replicate in 
ISG15 
-/- 
cells but was inhibited in wild type cells. However, it is not clear if the E3 
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protein is actually responsible for the ISG15 inhibition since transduction of ISG15 in 
both knock out and wild type MEFs was able to inhibit not only the virus lacking E3 but 
also the wild type virus. Hence while establishing that ISG15 indeed has an antiviral 
activity against vaccinia virus, the study does not establish if the virus has any defense 
against ISG15 that is mediated by the E3 protein. Insights into the mechanism of ISG15’s 
antiviral activity come from studies on HIV and Ebola viruses. Both these viruses are 
inhibited at the budding stage by ISG15 (Okumura, Lu et al. 2006), (Okumura, Pitha et 
al. 2008). In HIV life cycle, the ubiquitination of Gag poly-protein and the interaction of 
Gag with the cellular protein Tsg101 is important for the budding of HIV virions. Ectopic 
expression of ISG15 and/or UBE1L inhibited the ubiquitination of both Gag and Tsg101 
and also inhibits Gag-Tsg101 interaction (Okumura, Lu et al. 2006). siRNA knock down 
of ISG15 in this study also rescued interferon mediated inhibition of HIV virion budding. 
Two studies have shown the effect of ISG15 on Ebola virus matrix protein VP40 
(Okumura, Pitha et al. 2008), (Malakhova and Zhang 2008). Ubiquitination of VP40 is 
important for Ebola virus’ budding and this ubiquitination is mediated by the ubiquitin 
ligase Nedd4.  ISG15 is able to inhibit Nedd4 mediated ubiquitination of cellular proteins 
and Nedd4’s auto-ubiquitination. One mechanism by which this is accomplished is the 
binding of ISG15 to Nedd4 in immuno-precipitation experiments which prevents the 
formation of Nedd4-E2 (UbcH6) complexes (Okumura, Pitha et al. 2008). Furthermore, 
both these studies show that ISG15 alone is able to inhibit Nedd4 mediated ubiquitination 
of VP40 both in cell extracts and in VP40 VLPs (virus like particles). This inhibitory 
effect of ISG15 is mediated by disrupting the interaction of Nedd4 with VP40 through its 
PTPY late domain since a VP40 that contains a mutated PTPY motif is unaffected by 
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ISG15. Many other HECT domain containing Nedd4- like E3 proteins are also able to 
mediate budding of VP40 VLPs and expression of ISG15 alone is able to almost 
completely inhibit this activity (Malakhova and Zhang 2008).  
Some viruses have developed strategies by which they can counter the effects of 
ISG15. Ovarian tumor (OTU) domain is present on many eukaryotic, bacterial and viral 
proteases. Some of these proteins have ubiquitin- deconjugating activity. Some RNA 
viruses like nairoviruses and arteriviruses have been shown to have OTU domain 
containing proteins. The L protein of the nairovirus, crimean congo hemorrhagic fever 
virus (CCHFV) has an N terminal OTU domain the expression of which is able to reduce 
the overall levels of ubiquitinated and IGGylated proteins in a transfection system as well 
as cleave poly-ubiquitin chains and ISGylated proteins in vitro (Frias-Staheli, 
Giannakopoulos et al. 2007). Transgenic mice expressing the OTU domain of L protein 
were much more susceptible to infection by a virulent sindbis virus strain, AR86 as 
compared to the control mice. These results show that viral OTU domains could target 
the ubiquitin and ISG15 pathways in host innate immune responses. Another viral 
protein, the SARS coronavirus papain like protease (SARS CoV PLpro), in addition to 
processing the viral polyprotein, is also a deubiquitinating enzyme that preferentially 
debranches lysine 48 linked ubiquitin chains (Lindner, Fotouhi-Ardakani et al. 2005). It 
also preferentially processes ISG15 precursors (Lindner, Lytvyn et al. 2007). The reason 
why such activity would be of benefit to the virus still needs to be worked out. 
ISG15 is not an essential gene as knock out mice show normal development 
(Osiak, Utermohlen et al. 2005). Moreover, although ISG15 has been shown to have 
antiviral activity against many viruses, it does not show a universal antiviral role. For 
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example, ISG15 is not essential for host response against vesicular stomatitis virus (VSV) 
and lymphocytic choriomeningitis virus (LCMV) in ISG15 
-/- 
mice. A previous report had 
suggested that ISG15 has a role to play in STAT1 signaling, as mice lacking a protease 
(UBP43) that depleted ISG15 conjugates showed increased STAT signaling (Malakhova, 
Yan et al. 2003). However the ISG15 knock out mice did not show decreased STAT 
signaling. There was also no increased secretion of IFNγ in the serum of the knock out 
mice upon VSV and LCMV challenge. These results show that role of ISG15 is critical to 
protect the host against certain viruses while dispensable against others. ISG15 could 
play a broader role in the host’s innate response to infection not only to viruses but also 
to intracellular bacteria. Recently, it has been shown that Leishmania braziliensis 
infection induces ISG15 (Vargas-Inchaustegui, Xin et al. 2008), as does bacterial 
lipopolysaccharide (LPS). 
Influenza B virus is currently the only known virus that encodes a protein that directly 
binds ISG15 (Yuan and Krug 2001). NS1B reduces the intracellular levels of ISG15 
conjugates in transfection experiments (chapter 2). Hence, it is hypothesized that ISG15 
(and/or) conjugation plays an important anti-viral role in the life cycle of influenza B 
virus and NS1B inhibits these activities. While many of the previously mentioned studies 
on ISG15 use ectopic over expression of ISG15 to study its role in antiviral activity 
(Okumura, Pitha et al. 2008), (Okumura, Lu et al. 2006), (Lenschow, Giannakopoulos et 
al. 2005), (Guerra, Caceres et al. 2008), influenza B virus offers a unique possibility of 
making a mutant virus in which the NS1B is unable to bind ISG15. Such a virus would 
afford a system where the role of ISG15 can be studied in tissue culture without any over 
expression of ISG15 and therefore will be physiologically relevant. Such a mutant virus 
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would be predicted to be attenuated as compared to the wild type and would be able to 
provide insights into the mode of action of ISG15. In the current study, the ISG15 
binding site was determined and a mutant virus generated whose NS1B contained a 
mutated ISG15 binding site. The characterization of this mutant virus is the one of the 
major focuses of my dissertation. 
1.8 INTRA NUCLEAR COMPARTMENTS AND SC35 SPECKLES 
 
The nucleus is a highly compartmentalized structure, with several components 
(both nucleic acids and proteins) organized into distinct sub nuclear compartments, like 
nucleolus, PML bodies, cajal bodies, gems, para speckles, and SC35 speckles (Spector 
1993), (Lamond and Spector 2003). These compartments show punctuate distribution in 
microscopy and are usually identified by microscopy as well as the presence of 
characteristic proteins.   
SC35 speckles or splicing speckles are named for the characteristic accumulation 
of the splicing factor SC35 in these structures. Each cell contains 20-50 SC35 speckles 
depending on the stage of the cell cycle and the transcription state of the cell. In electron 
microscopy, speckles are divided into two distinct domains:  ‘core’ inter chromatin 
granules (ICGs), each 20-25nm in diameter, and ‘fibrilar extensions’ at the edges of the 
ICGs called perichromatin fibrils (PFs). Besides the periphery of the speckles, PFs are 
also found at other regions of the nucleus, far away from the speckles (reviewed in 







Figure 1.10 Protein composition of splicing (SC35) speckles. Pie chart showing the 
distribution of protein classes contained in mouse liver speckles. One 
hundred forty six proteins identified in speckles are classified based on their 






1.8.1 Composition of speckles 
The protein composition of the speckle has been identified using a biochemical 
purification of the nuclear speckles from mice liver followed by mass spectrometry 
(figure 1.10) (Mintz, Patterson et al. 1999), (Saitoh, Spahr et al. 2004). In these studies, 
146 proteins were identified out of which 81% were involved in RNA metabolism. This  
included proteins involved in transcription (RNA polymerase II subunits), mRNA export, 
RNA binding proteins and pre-mRNA splicing, which comprised of over 50% of the 
identified proteins. The splicing factors SR proteins are especially enriched in speckles. 
SR proteins are a conserved family of proteins involved in a wide variety of activities in 
both constitutive and regulated splicing (Zahler, Lane et al. 1992), (reviewed in (Fu 
1995), (Valcarcel and Green 1996), (Kramer 1996)), and are characterized by the 
presence of one or two RNA recognition motifs (RRMs) and a RS domain, which 
contains many tens or hundreds of repeats of the dipeptide, arginine-serine. The RS 
domain has been proposed to play a role in protein-protein interactions, and is also 
heavily phosphorylated at the serine residues present in this domain (reviewed in (Stamm 
2008)). Besides proteins, speckles also contain a stable pool of poly A+ RNA (Carter, 
Taneja et al. 1991), (Visa, Puvion-Dutilleul et al. 1993), (Huang, Deerinck et al. 1994). 
This RNA population is not exported into the cytoplasm (Huang, Deerinck et al. 1994); 
therefore it is proposed that these either play a structural role in the maintenance of the 
speckles or represent defective mRNAs. The function of this RNA population in the 
speckles is still under study. 
Analysis of the proteins identified in the speckle did not reveal any single 
common motif that could target them to these speckles. Indeed, several different speckle 
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targeting domains have been described. One of the well studied domain is the RS domain 
of SR proteins. Some SR proteins like SC35 and SRp20 contain a single RNA 
recognition motif (RRM) and RS domain. For these proteins, the RS domain is important 
for speckle localization (Caceres, Misteli et al. 1997). The RS domain is also necessary 
and sufficient for speckle localization of Drosophila proteins like Tra and SWAP which 
do not contain a RRM (Li and Bingham 1991; Hedley, Amrein et al. 1995). Some SR 
proteins like SF2/ASF and SRp40 contain not one but two RRMs. In these proteins, the 
RS domain is not required for speckle localization per se but might be involved in 
nuclear targeting (Caceres, Misteli et al. 1997). In these proteins, any two of the three 
domains are required for speckle localization. Besides the RS domain, other speckle 
localization signals have been described. The polyhistidine tail of the kinase DYRK1A 
(Alvarez, Estivill et al. 2003), two contiguous sequences rich in arginine, proline and 
serine in the SR related protein SRm160 (Wagner, Chiosea et al. 2003), the ankyrin 
repeat of IќBL protein (Semple, Brown et al. 2002) and the fork-head domain of protein 
phosphatase I regulator NIPP1 (Jagiello, Van Eynde et al. 2000) have all been shown to 
act as speckle targeting motifs in those respective proteins. For some proteins, the nuclear 
and speckle localization signals can be separated, but for others, these seem to be 
inseparable. In summary, it can be concluded that the signals mediating speckle 
localization vary widely between different proteins.  
1.8.2 Model of speckle function 
 
The exact function of the speckles has been the subject of debate. One model 
suggests that the speckle plays an active role in mRNA processing and screening for 
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defective mRNA before it is exported to the cytoplasm (reviewed in (Hall, Smith et al. 
2006)). The other more commonly accepted model proposes that the speckles act more 
like sites of storage or assembly for splicing and transcription factors from where they are 
recruited to the perichromatin fibrils, which are sites of active transcription and RNA 
processing (Jimenez-Garcia and Spector 1993). Indeed, speckles are dynamic structures 
and although the position of the speckles themselves remained constant in the nucleus, 
there is a constant movement of factors to and from the speckles in inter-phase nuclei. 
Time lapse microscopy of GFP tagged splicing factor SF2/ASF showed movement at the 
periphery of the speckles (Misteli, Caceres et al. 1997). Several conditions regulate the 
movement of factors to and from the speckles as well as their morphology. The 
movement of GFP tagged SF2/ASF did not occur when the cells were treated with α 
amanitin, a RNA polymerase II inhibitor (Misteli, Caceres et al. 1997). Conversely, in 
virus infected cells in which transcription occurs at high rates, the speckles disperse and 
lose their compact rounded structures (Bridge, Xia et al. 1995). The status of 
phosphorylation of the SR proteins also affects speckle assembly. The serines in the SR 
domain of these proteins are phosphorylated by kinases like SRPK-1 (Gui, Lane et al. 
1994) and CLK/SKY (Colwill, Pawson et al. 1996). Phosphorylation regulates the 
association of SR proteins in the spliceosome (reviewed in (Stamm 2008)). When SRPK-
1 was added to permeabilized cells or CLK/SKY was over expressed, the splicing factors 
were released from the speckles into the nucleoplasm, while protein phosphatase-1, 
which dephosphorylates SR proteins, causes enlargement and rounding of speckles 
(Misteli and Spector 1996). Similarly, inhibition of splicing by microinjection of oligo-
nucleotides or antibodies into cells  also cause the speckles to enlarge, become fewer in 
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number and round up, suggesting an accumulation of splicing factors in these bodies 
(O'Keefe, Mayeda et al. 1994).  
1.8.3 NS1B and SC35 speckles 
It has been observed in my research (chapter 3) and others’ (Schneider, Dauber et 
al. 2009) that NS1B localizes to SC35 speckles. At the time of initiation of this study, the 
speckle localization of NS1B was not characterized or previously reported. NS1B 
localizes to the speckles at early times post infection as well as in transfection 
experiments, indicating that other viral proteins are not required for this activity. Also, N 
terminal tagging of NS1B with V5 or GFP did not affect the localization (chapter 3). 
Subsequently, a paper was published which described the localization of NS1B to 
speckles (Schneider, Dauber et al. 2009). Both my data as well as this study show that at 
least part of the localization sequence is found within the N terminal 93 amino acids of 
the protein. However, this study failed to identify a specific sequence necessary for 
speckle localization that was distinct from the nuclear localization signal (NLS).  In this 
study (chapter 3), I show that speckle localization signal is different from the NLS and is 
contributed by both N and C terminus of NS1B. The reason for NS1B’s localization is 
intriguing. NS1A which binds PABII(a speckle localized protein), is not localized to 
speckles. Rather, NS1A draws out PABII from speckles to  the nucleoplasm (Chen, Li et 
al. 1999). NS1B does not bind PABII or CPSF30 and does not inhibit 3’ end processing. 
NS1B also has no characterized effect on the host splicing machinery (Wang and Krug 
1996). Therefore the function of this sub-nuclear compartmentalization of NS1B is not 
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known. The current study was initiated to further characterize the localization of NS1B; 
in particular, identify regions of the protein that could act as the targeting signals. 
 Relatively little is known about the strategies used by influenza B virus for its 
replication and suppression of host response. My research has focused on the 
characterization of NS1B protein of influenza B virus in an effort to better understand the 
functions of this protein in virus infection. In particular, I have focused on two properties 
of the NS1B protein that are not shared by its counterpart in influenza A viruses, NS1A, 
namely, binding of NS1B to the host factor ISG15 (chapter 2) and its unique intra-nuclear 
localization to splicing speckles (chapter 3). By characterizing these two functions, my 
research aims to shed further light into the strategies adopted by influenza B virus for its 
replication and in combating host immune response. One of the goals of my research was 
study the importance of NS1B-ISG15 interaction during influenza B virus infection using 
a recombinant virus which encodes an NS1B cannot bind ISG15. Another goal of my 
study was to further characterize the intra-nuclear localization of NS1B to nuclear 




CHAPTER 2: Influenza B virus NS1 protein exhibits species specific 
interaction with ISG15 
 
2.1 INTRODUCTION  
 
 Interferons (IFNs) form a crucial component of the innate immune response to 
viruses and other intra-cellular pathogens. Upon IFN induction, hundreds of genes are 
induced whose products are involved in inhibiting various stages of the viral life cycle or 
inducing host cell apoptosis (de Veer, Holko et al. 2001). Interferon stimulated gene 15 
(ISG15) is one of the earliest and most strongly induced genes by type I interferons (IFN 
α/β). Upon IFN induction, ISG15 is conjugated to hundreds of intracellular proteins 
through an enzymatic cascade involving an E1 activating enzyme, E2 conjugating 
enzyme and E3 ligating enzyme (figure 1.8, reviewed in (Sadler and Williams 2008)). It 
is first attached to the E1 activating enzyme (UBE1L) (Yuan and Krug 2001) through a 
thioester bond in its active site, from where it is transferred to the conjugating enzyme 
(UBCH8) (Zhao, Beaudenon et al. 2004) again forming a thioester bond mediated 
complex with the E2. Finally it is conjugated to target proteins via an E3 ligase (HERC5) 
(Dastur, Beaudenon et al. 2006), (Wong, Pung et al. 2006). ISG15 and its conjugation 
have been shown to have anti-viral activities against several viruses (Lenschow, Lai et al. 
2007), (Okumura, Lu et al. 2006), (Okumura, Pitha et al. 2008), (Guerra, Caceres et al. 
2008), (Lai, Struckhoff et al. 2009). In many of these cases, ISG15 alone can inhibit the 
viruses, with the exception of influenza A virus, where it was shown in our laboratory 
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that conjugated and not free ISG15 is important for the inhibition (Hsiang, Zhao accepted 
for publication).  
The non structural protein 1 of influenza B viruses (NS1B) plays an important 
role in the viral life cycle since a deletion of it from the virus dramatically attenuates the 
virus in both interferon competent as well as deficient cells (Dauber, Heins et al. 2004). 
NS1B shares a similar N terminal dsRNA binding domain as its counterpart in influenza 
A viruses (NS1A) (Wang and Krug 1996), (Yin, Khan et al. 2007). However this region 
also contains certain unique features that are not conserved between the two proteins. 
One such feature is the binding of NS1B but not NS1A to ISG15 (Yuan and Krug 2001). 
The region of NS1B that is necessary for this binding is contained within the N terminal 
103 amino acids. Using GST binding assays, it was determined that part of the binding 
site on NS1B was contributed by the 1-93 amino acids that constitute the dsRNA binding 
domain and the other part of the binding site was contributed by amino acids between 93 
and 103 (Yuan and Krug 2001). The binding to ISG15 and dsRNA by NS1B are 
independent of each other, and can occur simultaneously resulting in a super complex 
(Yuan, Aramini et al. 2002). Initially, it was proposed that loop1 of NS1B (the loop 
between alpha helices 1 and 2) was involved in ISG15 binding since mutations in this 
loop disrupted binding. However, this mutant was based on a structure prediction for N 
terminus of NS1B (Yuan, Aramini et al. 2002), which has been subsequently proven 
wrong (Yin, Khan et al. 2007).  
In this study, we identified the correct binding site of ISG15 on NS1B. We 
identified a role for helix 3 in the RNA binding domain of NS1B in the binding of ISG15. 
Further, we identified a residue between amino acids 93 and 104 also involved in 
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binding, thus confirming the previous study that predicted a role for both these two 
regions in binding ISG15. We introduced this mutation into the virus by reverse genetics 
to generate a recombinant B/Yamanashi/98 virus whose NS1B cannot bind ISG15. We 
show that the wild type NS1B is able to sequester ISG15 into intra nuclear speckles in 
infected cells while the mutant NS1B is unable to do so. Furthermore, we determined the 
species specific nature of the interaction between ISG15 and NS1B by showing that 
NS1B binds to ISG15 from humans and old world monkeys, but not to mouse or canine 
ISG15. Consistent with this data, a recombinant Influenza B virus which encodes a NS1B 
protein that does not bind ISG15 is attenuated in human cells but not in canine cells. We 
also identified an important role for the hinge region between the N and C terminal 
‘ubiquitin-like’ domains of ISG15 in determining species specificity. Our results have 
highlighted the importance of using human tissue culture systems in studying the role of 
host factors in influenza B virus infection. 
2.2  MATERIALS AND METHODS 
Cell lines and plasmids 
  
Madin-Darby canine kidney cells (MDCK) (ATCC CCL-34), African green 
monkey Cos7 (ATCC CRL-1651), human lung carcinoma cells A549 (ATCC CCL-185) 
and Calu-3 (ATCC HTB-55) were purchased from ATCC. Hela tet-on cells were 
purchased from Clonetech (catalog # 630901). MDCK, Cos7, 293T, A549 and Hela tet-
on cells were cultured in DMEM (GIBCO 
®
) supplemented with 10% heat inactivated 
fetal bovine serum (FBS) (GIBCO 
®
), and 2mM 1- glutamine, 100units/ml penicillin and 
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C with a 5%CO2/95% air atmosphere. Calu-3 
cells were cultured in Advanced MEM (GIBCO 
®
) supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (GIBCO 
®
), and 2mM 1- glutamine, 100units/ml 




C with a 5%CO2/95% air 
atmosphere. 
Expression of GST tagged proteins in bacteria and their large scale purification by 
glutathione sepharose affinity selection 
 
 For expression of proteins for in vitro ISG15 binding assay, the DNA for NS1B 
wild type or mutant (AAA) full length was cloned into expression vector pGEX4T2 
(Amersham) using the sites BamH1 and Xho1 on the vector and 5’ BglII and 3’ XhoI for 
the insert. The enzyme sites were introduced into the ends of NS1B DNA by PCR based 
mutagenesis. For in vitro thio-ester assays, DNA for NS1B full length was cloned into 
pGEX3X vector (Amersham) using BamH1 site on the vector and BglII on insert. DNA 
for ISG15 was cloned into pGEX4KT plasmid and pGEX-UBCH8 plasmid was obtained 
from Dr. Brenda Schulmann (St. Jude’s Children’s hospital, Memphis, Tennessee). 
 Single colonies of E.coli DH5α strain transformed with the above plasmids were 
grown in 1litre of LB containing 100ug/ml ampicillin. Protein expression was induced by 
0.1M IPTG (isopropyl thio galactoside) for 3-4 hours at 37ºC. Cells were pelleted, 
washed and re-suspended in 15ml of ice cold PBS along with Complete EDTA free 
protease inhibitor (Roche). Cells were lysed using sonication, and addition of 1.5 ml of 
10% triton X 100 detergent. The cell debris was pelleted by centrifuging the samples at 
13,000 rpm for 45 minutes in Beckman centrifuge. The supernatant was added to a 
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prepared column with a 1ml bed volume of glutathione sepharose beads (GE Healthcare). 
After washes with PBS and PBS/0.1% triton X 100, the bound proteins were eluted with 
glutathione elution buffer (10mM glutathione and 50mM Tris pH8.0). Protein purity and 
concentration were confirmed by SDS gel analysis and Bradford’s assay. 
In vitro GST binding assay 
 
 Bacterially purified GST NS1B wild type or AAA mutant protein (5µg) was 
bound to 30µg glutathione sepharose beads (GE Healthcare) for 2hr at 4ºC along with 
200µl of extracts from Hela cell that were treated with 1000units of human IFNβ for 40h 
(extracts were prepared in 1% NP40 containing lysis buffer) in the presence of buffer 
containing 25mM Tris-Cl pH8.0, 50mM NaCl and protease inhibitors. Beads were then 
washed with T25N50 buffer containing 0.1% NP40 before being boiled. Bound proteins 
were separated by 12% SDS PAGE and subjected to immunoblotting with rabbit anti 
NS1B or rabbit anti ISG15 (raised against GST ISG15 by Cocalico) antibodies.  
GST binding assay from transfected 293T cell extract 
 
 293T cells in 6 well plates were transfected with plasmids encoding NS1B and 
GST tagged ISG15 wild type or mutants (generated by PCR based mutagenesis) that 
were cloned into the PCN vector. 24-48h post transfection, cell lysates were prepared in 
200µl of lysis buffer (50mM Tris pH7.5, 150mM NaCl, 5mM EDTA, 2.5mM MgCl2, 1% 
NP40, 10% glycerol and protease inhibitor). Cell lysate (100-120µl) was mixed with 
equal volume of lysate dilution buffer (50mM Tris pH 7.5 and 150mM NaCl) and added 
to 50-60µl of glutathione sepharose beads (GE Healthcare) and incubated on a rotator in 
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4ºC for 3-4h. Beads were then washed with wash buffer (20mM Tris pH 7.5, 150mM 
NaCl and 0.5% NP40) three times before being boiled. Proteins bound to beads were 
separated by 2% SDS PAGE and detected by immunoblotting with anti NS1B or anti 
GST antibodies to detect NS1B and GST fused to ISG15 respectively.   
Generation and amplification of recombinant influenza B/Yamanashi/1998 viruses 
 
 The desired mutation (AAA) in NS1 gene was generated by PCR based 
mutagenesis and cloned into the Bsmb1/Esp3I sites of a pCDNA3 based pAD3000 
plasmid vector. Recombinant viruses were developed using the eight- plasmid based 
reverse genetics system described previously (Hoffmann, Mahmood et al. 2002). Briefly, 
cos7 cells were co-cultured with MDCK cells in six well plates and co-transfected with 
eight pAD3000 plasmids, each having one genomic segment of the virus cloned into it.  
Each viral segment is flanked by a RNA polymerase I and RNA polymerase II promoter. 
Inside the cell, transcription from the RNAPII promoter would give rise to positive sense 
capped and poly-adenylated mRNAs which are translated into viral proteins. 
Transcription from the RNAPI promoter gives rise to full length negative strand viral 
RNA segments which together with the viral proteins form vRNP complexes. Viruses are 
budded off from the surface of the cos7 cells and harvested from the supernatant. When 
co-cultured with MDCK cells, virus released from cos7 cells is amplified in MDCK cells 
to yield higher titer.  
 The N terminal 3xflag wild type NS virus was generated by Park, J.W in our 
laboratory (unpublished data). Following a similar strategy, a 3Xflag sequence was 
introduced into the N terminus of AAA mutant NS gene by a two step PCR, in which the 
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first PCR used a 5’ primer that partially overlapped with the 5’primer used in the second 
PCR, together generating the full sequence of the 3X flag tag. The final PCR product was 
digested with Bsmb1/Esp3I and cloned into a similarly digested pAD3000 plasmid. This 
plasmid was then used in the reverse genetics system to generate the 3Xflag tagged AAA 
virus as described above.  
Viruses were amplified by injecting 100µl of cell supernatant from reverse 
genetics experiment (diluted in serum free DMEM) into the allantoic cavity of ten day 
old embryonated chicken eggs, followed by incubation at 33ºC for 2 days. For virus 
amplification in MDCK cells, the cells were infected with dilutions of virus in serum free 
DMEM and allowed to adsorb for 1hr at 34ºC after which the cells were washed and 
incubated with opti-MEM containing 2.5µg/ml N acetyl trypsin (NAT) and 1% bovine 
serum albumin (BSA). Influenza B wild type and AAA mutant viruses were amplified in 
ten day old embryonated eggs. 3xflag wild type and AAA mutant viruses were amplified 
in MDCK cells. 
For virus sequencing, the viral RNA was extracted from egg or MDCK amplified 
virus using Qiagen viral RNA extraction kit. The vRNA was then used as template in 
reverse-trancription (RT) reaction using Roche RT kit and random hexamers as primers 
to generate complementary strand RNA. The NS (or other viral genes) were amplified 
using PCR and segment specific primers. The sequence was confirmed by sequencing of 




 For multiple cycle infections, MDCK or Calu-3 cells were grown to 80-90% 
confluency in 60mm dishes, washed with PBS, and incubated with virus diluted in serum 
free DMEM, at an multiplicity of infection (moi) of 0.001. After 1hr of adsorption at 
34ºC, the innoculum was removed, cells were washed with PBS and over-layed with opti-
MEM supplemented with 1% penicillin streptomycin glutamate (PSG) along with 
2.5ug/ml N acetyl trypsin (NAT). At specific time points, the supernatants were taken for 
titer determination by plaque assay. To assay for the requirement of NAT in multiple 
cycle growth in calu-3, the incubation media lacked NAT or NAT of 1 or 2.5 ug/ml.  For 
multiple cycle infections of Hela tet-on and A549 cells, these cells were grown on 
collagen coated 60mm dishes (for collagen coating, 2-3ml of 0.01% weight/volume of rat 
tail collagen I (Sigma; stock concentration 0.1% weight/volume in 0.1M acetic acid) in 
PBS was added to dishes, and let sit for 2-3hr in the 37ºC incubator, after which the 
collagen was removed and plates allowed to dry before plating cells), and infected with 
virus at a moi of 0.01. After adsorption, the cells were washed and over layed with opti-
MEM supplemented with 1µg/ml NAT. 0.5µg/ml NAT was replenished every 36hr.  
 For single cycle infections, cells were infected with virus diluted in serum free 
DMEM, at a moi of 2-5. After adsorption, the cells were washed three times with PBS, 
and over-layed with opti MEM containing 1% PSG. At specific times post infection, the 
cells were processed for Western blot or immunofluroscence analysis.  
Viral titer determination by plaque assay 
 
MDCK cells were grown to confluency on 60mm dishes. Prior to infection, the 
media was removed and cells washed with PBS. Dilutions of influenza B virus wild type 
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or AAA mutant (in serum free DMEM) were added to the cells and allowed to adsorb for 
1hr at 34ºC. Cells were washed with PBS, and over-layed with serum free DMEM 
containing a final concentration of 2.5ug/ml N acetyl trypsin and 1% agarose. Once the 
agarose solidified, the plates were inverted and incubated at 34ºC for 3-5 days until 
plaques start to appear. At the time of staining, the agarose was removed and the cells 
stained with Naphthalene blue-black stain (1g Napthalene blue black powder, 60ml 
glacial acetic acid, 13.6g anhydrous sodium acetate in 1 liter distilled water) for 10min at 
room temperature to count the plaques.  The viral titer is calculated by the following 
formula: 
Viral titer = # of plaques*dilution factor/ volume of innoculum 
Immunofluroscence and confocal microscopy 
 
 Hela tet-on cells were grown in four chamber cover glass bottom microscopic 
slide (Lab Tek) and transfected or infected as desired. At the desired time, the cells were 
washed with PBS and fixed with 4% paraformaldehyde for 20 minutes at room 
temperature. Following three washes with PBS, the cells were permeabilized in 0.5% 
tween 20 in PBS for 10 minutes on ice. Cells were then washed three times with PBS and 
incubated in blocking solution (PBS-NGS-gelatin; 0.5ml of 100% normal goat serum and 
0.2ml of 10% gelatin in 1X PBS) for half an hour at room temperature followed by 
incubation with primary antibody (1:200 dilution in PBS-NGS-gelatin blocking solution) 
for one hour at room temperature or overnight at 4ºC. Primary antibodies used included 
rabbit anti NS1B antiserum (raised against GST NS1B), mouse anti SC35 monoclonal 
antibody (Sigma), mouse anti flag M2 monoclonal antibody (Sigma) and ferret anti 
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influenza B/Memphis antiserum (kindly provided by Dr. McCullers, St. Jude’s Children’s 
hospital, Memphis, Tennessee). Following incubation with primary antibody, the cells 
were washed 3 times with PBST (PBS with 0.1% tween 20), and incubated with 
secondary antibody (1:200 dilution in blocking buffer) in dark for 30 minutes at room 
temperature. Secondary antibodies used included goat anti rabbit IgG conjugated to 
TRITC (Jackson Labs), goat anti mouse IgG that was TRITC (Jackson Labs) or FITC 
(Sigma) conjugated and goat anti ferret IgG that was FITC conjugated (Bethyl 
laboratories). After incubation with secondary antibody, the cells were washed as 
described above (in dim light), stained with DAPI (1µl of 1mg/ml stock concentration in 
15ml PBS) in dim light, washed with PBS and then observed using the 40X oil 
immersion objective in the Leica confocal microscope at the U.T Austin ICMB core 
facility. The images were processed by LCS Lite software.  
Transfections 
 
 Transfections were carried out using Mirus transfection reagent according to the 
manufacturer’s protocol.  
Immunoblotting and antibodies 
 
Proteins were resolved on 10-12% SDS PAGE using the Biorad mini-gel system, 
and transferred to a nitrocellulose membrane using semi-dry Western transfer apparatus 
using 0.8mA/cm
2 
current. For immunoblotting, membranes were blocked with TBST 
(Tris Borate Saline containing 0.2% tween 20) containing 5% milk for 30 minutes at 
room temperature, followed by incubation with primary antibody diluted in blocking 
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buffer for 1-2h at room temperature or overnight at 4ºC. Primary antibodies used 
included rabbit anti GST NS1B antiserum (1:1500 dilution), goat anti GST antibody 
(1:10,000 dilution), rabbit anti ISG15 antiserum (1:1000 dilution), rabbit anti P56 
antiserum (1:1000 dilution), mouse anti flag M2 monoclonal antibody (Sigma, 1:1000 
dilution) and mouse anti tubulin monoclonal antibody (1:1000 dilution). Following 
incubation with primary antibodies, the membrane was washed three times with 15-20ml 
of TBST for 10 minutes each at room temperature, and then incubated with secondary 
antibody diluted in blocking buffer for 1h at room temperature. Secondary antibodies 
used included goat anti rabbit IgG conjugated to HRP (Zymed, 1:10,000 dilution), goat 
anti mouse IgG conjugated to HRP (Zymed, 1:10,000 dilution), or donkey anti goat IgG 
conjugated to HRP (Santa Cruz, 1:10,000 dilution). Following incubation with secondary 
antibody, the membrane was washed with TBST as described above and developed with 
Pierce ECL chemiluminscent substrate. For ISG15 westerns, the blot was developed 
using Pierce supersignal west pico chemiluminescent substrate. 
In vitro assay to detect ISG15 thiol ester bond formation with UBE1L and UBCH8 
 
For preparation of 
32
P labeled ISG15, 5µg of bacterially expressed GST ISG15 
protein was bound to glutathione beads for 2 hours on a rotator at 4ºC. Beads were 
washed with PBS and kinase buffer (40mM Tris pH7.5, 20mM MgCl2), and then 
incubated with 5µl of gamma 
32
P labeled ATP in the presence of kinase buffer for 30 
minutes at room temperature. Following two washes with PBS, and one wash with 
thrombin buffer (50mM Tris pH8.0, 150mM NaCl, 2.5mM CaCl2 and 0.04mM  MgCl2), 
GST was cleaved off the labeled ISG15 protein by addition of biotinylated thrombin 
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(Novagen) in presence of thrombin buffer. The supernatant was incubated with 
streptavidin agarose beads (Novagen) to bind the biotinylated thrombin, and passed 
through cleavage capture columns to get rid of the agarose beads. The 
32
P labeled ISG15 
was frozen or used in in vitro assays to detect thiol ester bond formations with UBE1L or 
UBCH8.  
Purified GST UBE1L was obtained from Dr. Brenda Schulmann (St. Jude’s 
Children’s Hospital, Memphis, Tenneesse). GST was cleaved off UBE1l by Tev protease 
and dialysed (dialysis exchange buffer contained 50mM Tris pH8.0, 150mM NaCl and 
0.5mM DTT) before storage at -80ºC in aliquots. GST UBCH8 was purified from 
bacteria, GST was cleaved using biotinylated thrombin (as described above), and UBCH8 
was dialysed (see dialysis buffer above) before storage at -80ºC. Thio-ester assays were 
set up in 40µl reactions in T25N50 buffer containing 0.1mM DTT, 10mM MgCl2 , 
7.5mM ATP, 2µl of 
32
P labeled ISG15, 1.4µg of purified UBE1L, 1.65µg of purified 
UBCH8 and 10µg of GST NS1B proteins as indicated. The reactions were incubated at 
room temperature for 10 minutes, after which they were boiled in SDS buffer lacking 
DTT to detect thiol ester bond. Buffer containing DTT was used as control to confirm 
that these bonds were sensitive to DTT.  
2.3 RESULTS 
 
2.3.1  Identification of ISG15 binding site on NS1B 
 
From previous studies, it was shown that a C-terminal truncation of NS1B 
containing amino acids 1-104 was sufficient to bind ISG15 in in vitro GST pull down 
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assays. A smaller truncation of 1-93 amino acids, which comprised only the RNA 
binding domain was insufficient for this binding as were the amino acids from 95-104 
(Yuan and Krug 2001). This led to the conclusion that there were regions within the 1-93 
amino acids as well as between 93 and 104 amino acids that co-operatively form the 
surface for ISG15 interaction.  
The N terminal 1-93 amino acids of NS1B forms the dsRNA binding domain 
whose structure shows a dimer of NS1B in a six alpha helical fold with the dsRNA 
groove provided by conserved basic residues in alpha helix 1 and 2 (figure 1.6) (Yin, 
Khan et al. 2007). We took advantage of the fact that NS1A despite having a highly 
similar structure of its RNA binding domain did not bind ISG15. Chimeric proteins were 
made in which the helices in the RNA binding domain of NS1B were swapped with those 
of NS1A. The mutants were tested in a GST pull down assay to test their binding to 
ISG15. This experiment indicated a role for helix 3 of NS1B in ISG15 binding (Zhao and 
Krug, data not shown). Based on the structure of the RNA binding domain, various 
surface exposed residues were mutated. Two kinds of mutations were made, ones in 
which the amino acids in NS1B were mutated to the corresponding amino acid in NS1A 
(figure 2.1A, lanes 5 and 6), and others in which the residues in NS1B were mutated to 
alanines (figure 2.1A, lanes 7-9). The binding of these mutants to ISG15 were tested in 
GST pull down assays (figure 2.1A). Several of these mutants involving amino acids 
valine 87, phenylalanine 90 and methionine 91 were defective in ISG15 binding (figure 
2.1A, lanes 5-9). In addition to these residues in the RNA binding domain, phenlyalanine 
100, which is between the RNA binding domain and amino acid 104 also contributed to 
binding (figure 2.1A, compare lanes 7 and 8).  The NS1B triple alanine mutant of 
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V87AM91AF100A (figure 2.1A, lane 9) was chosen for future analysis. This mutation 
will henceforth be referred to as the ‘AAA mutant’. Figure 2.1B shows a schematic 
representation of the N terminal 1-104 amino acids of NS1B with the residues 87, 91 and 
100 indicated by a star. To confirm that the AAA mutant indeed does not bind ISG15, a 
reverse in vitro pull down experiment was conducted (figure 2.1C). Bacterially expressed 
GST NS1B wild type (figure 2.1C, lane 1) but not the AAA mutant protein (figure 2.1C, 
lane 2) was able to bind both free and conjugated ISG15 from IFN treated Hela cell 
extracts. 
 
2.3.2 Generation of a recombinant Influenza B virus encoding an AAA mutant 
NS1 protein 
The ‘AAA’ mutation identified above was then introduced into influenza B virus 
by the eight plasmid based reverse genetics system described previously (Hoffmann, 
Mahmood et al. 2002). Sequencing of the viral RNA of the recovered virus confirmed 
that the NS gene encoded the desired AAA mutation in NS1B. The virus was amplified 
by injecting purified plaques into the allantoic cavity of ten day old embryonated chicken 
eggs. This mutant virus shall henceforth be referred to as the AAA mutant virus. 
2.3.2.1 NS1 from AAA mutant virus does not bind ISG15 in infected cells 
 
To confirm that the NS1B protein of the AAA mutant virus indeed did not bind 
ISG15 in infected cells, we tested the binding of the virally encoded AAA mutant NS1B 




Figure 2.1  Identification of ISG15 binding site on NS1B (AAA mutant). A.293T 
cells were transfected with plasmids encoding GST (lanes 1-2) or GST-
ISG15 (lanes 3-9) along with NS1B wild type (lanes 2,4) or indicated 
mutants (lanes 5-9). 24-48h post transfection, cell lysates were subjected to 
GST purification and proteins bound to beads were detected western 
blotting with anti NS1B or anti GST antibodies. B. Schematic representation 
of NS1B showing N terminal 104 amino acids. Amino acids involved in 
ISG15 binding are indicated by a star. C. 5 µg of bacterially purified GST 
NS1B wt (lane 1) or AAA mutant (lane 2) protein were bound to glutathione 
sepharose beads and incubated with equal amounts of extracts of Hela cells 
treated with 1000u of IFNβ for 40h for 2h at 4ºC. Beads were washed and 
boiled. Proteins bound to beads were separated by SDS PAGE an detected 
by western blotting with anti NS1B or anti ISG15 antibody to detect free 





   1            2 
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wild type virus bound the transfected GST-ISG15 (figure 2.2, lane2), NS1B from the 
AAA mutant virus did not (figure 2.2, lane 3), thus confirming that the NS1B from the 
mutant virus was unable to bind ISG15 in infected cells. 
 
2.3.3 Intracellular localization of AAA mutant NS1B 
 
To confirm that the AAA mutation does not disrupt the three dimensional protein 
structure of NS1B, we tested to see if AAA NS1B mutant protein still retained the correct 
cellular localization. NS1B accumulates in intra-nuclear compartments called the splicing 
speckles characterized by the staining of splicing factor SC35 (figure 2.3A).  In 
transfection experiments in Hela Cells, we observed that the AAA mutant NS1B protein 
also localized to these speckles (figure 2.3B), demonstrating that this function of the 
NS1B protein is not compromised by the AAA mutation.  
We next looked at the localization of NS1B during infection. To perform this 
experiment, we utilized a recombinant virus in which the NS gene encoded a NS1B 
protein with an N terminal 3X flag tag. This virus was developed in our laboratory and it 
has been shown that the N terminal tagging is not toxic to the virus (Park and Krug, 
unpublished results). Using the same PCR strategy (see materials and methods), the N 
terminal 3Xflag tagged AAA mutant NS was generated and introduced it into the virus by 
reverse genetics. The power of creating such a virus is the ability to use the anti flag 
antibody to detect the NS1B protein during infection, since the anti NS1B serum in our 
laboratory shows high background in immunofluroscence experiments. The N terminal 





Figure 2.2   NS1 from AAA mutant virus does not bind ISG15 in infected cells. 293T 
cells were transfected with plasmid encoding GST (lane 1) or GST-ISG15 
(lanes 2-3). 24h post transfection, the cells were infected with wild type 
(lanes 1-2) or AAA mutant (lane 3) virus. Cell lysates were prepared 12h 
post infection and subjected to GST purification over glutathione sepharose 
beads. Proteins bound to beads were separated on SDS PAGE and detected 




message and the two proteins share the same N terminal eleven amino acids (Briedis and 
Lamb 1982). However, the NS1 protein is expressed approximately ten times more 
abundantly than NS2 (data not shown); hence majority of the signal coming from the anti 
flag antibody in immunofluroscence represents the NS1 protein. The wild type NS1B 
protein localizes to the nucleus early during infection (figure 2.4; 3 and 5 hours), however 
at later times (figure 2.4; 7 hours post infection) is present in the cytoplasm. This is 
unlike the NS1A protein that is present in the nucleus for most the life cycle. One of the 
reasons for the cytoplasmic localization of NS1B could be because it binds ISG15 which 
is a cytoplasmic protein. To determine if this is the case, localization of the NS1B protein 
of the AAA mutant virus was observed over a time course of infection. The NS1B of this 
virus too followed a similar localization during infection, i.e. localizing to nuclear 
speckles in initial times post infection and present in the cytoplasm at later stages (figure 
2.4). These results indicate that the cytoplasmic localization of NS1B is not due to ISG15 
binding; rather, it could be due to other as yet unidentified cytoplasmic functions of 
NS1B.  
 
2.3.4  Re-localization of ISG15 into nucleus in influenza B infected cells 
 
Since it was established that the localization of AAA mutant was not changed due 
to lack of binding ISG15, the reverse effect was tested i.e, whether NS1B has any effect 
on the cellular localization of ISG15. Hela cells transfected with 3xflag ISG15 showed a 
cytoplasmic localization for ISG15 (figure 2.5A). This was observed previously, when it 




Figure 2.3  Nuclear localization of AAA mutant NS1B in transfection. Hela cells 
were transfected with plasmids encoding NS1B wild type (row A) or AAA 
mutant (row B). 24h post transfection, cells were fixed and subjected to 
immunofluroscence with rabbit anti NS1B and mouse anti SC35 antibodies. 
Secondary antibodies used were anti rabbit conjugated to TRITC and anti 
mouse conjugated to FITC. The merge column shows the merged signals 












Figure 2.4 Localization of AAA mutant NS1B during infection. Hela cells were 
infected with N terminal 3X flag tagged wild type or AAA mutant virus at 
an moi of 2-5. At 3, 5 and 7 hours post infection, the cells were fixed and 
immunofluroscence was performed with mouse anti flag antibody to detect 







(Loeb and Haas 1994). The transfected cells were then infected with wild type (figure 
2.5B) or AAA mutant virus (figure 2.5C).  As can be seen from the wild type infected 
cells, the ISG15 was dramatically re-localized into the nucleus, with very little 
cytoplasmic staining visible (figure 2.5B). Within the nucleus, ISG15 could clearly be 
seen enriched in SC35 speckles. We confirm that this re-localization of ISG15 is due to 
binding NS1B by showing that ISG15 is predominantly cytoplasmic during infection of 
the AAA mutant virus (figure 2.5C).  To detect infected cells, the anti-Memphis antibody 
(kindly provided by Dr. McCullers, St. Jude’s children’s hospital, Memphis) which was 
raised against B/Memphis virus and detects all the structural proteins of influenza B 
virus, was used. 
 In our experiments, we have observed that NS1B not only binds free ISG15, but 
also binds pre-formed ISG15 conjugates when the latter are present (figure 2.1C). 
Therefore, it is reasonable to predict that the wild type NS1B will be able to also re-
localize the conjugated ISG15 into the intra-nuclear SC35 speckles.  
 
2.3.5  AAA mutant virus is not attenuated in multiple cycle growth in MDCK cells 
 
The multiple cycle growth characteristics of the AAA mutant virus in MDCK 
cells were studied. MDCK cells are derived from canine kidney cells and are the 
predominant cells used in the field to grow influenza viruses in tissue culture. To study 
the multiple cycle growth of AAA virus, MDCK cells were infected with either wild type 
or AAA mutant influenza B virus at a low multiplicity of infection (moi=0.001) (figure 
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2.6). The AAA mutant virus is neither attenuated in growth kinetics nor final virus yield 
as compared to the wild type virus (figure 2.6).  
 
2.3.6 Screen for a suitable human tissue culture system to study influenza viruses 
 
The AAA mutant virus is not attenuated in MDCK cells which are canine kidney 
cells (figure 2.6). One of the reasons for the lack of attenuation could be that MDCK cells 
are not a suitable system to study the effect of ISG15 influenza B viruses. Influenza B 
virus is almost an exclusively human virus, unlike influenza A viruses which cause 
disease in a wide variety of mammals and birds. Further, the enzymes required for 
conjugation of ISG15, i.e UBE1L, UBCH8 and HERC5 as well as the targets have been 
characterized in human cells. Also the E3 enzyme, HERC5, is absent in certain other 
mammals like mice. Finally, but perhaps most importantly, NS1B does not bind canine 
ISG15 (refer section 2.4). All these reasons led us to search for a good human cell culture 
system to study the AAA mutant virus. 
Very few cell types support multiple cycle influenza virus growth in tissue 
culture. This restriction arises due to the requirement for the cleavage of the viral 
membrane protein, hemagglutinin (HA), in the absence of which the released viral 
particles are unable to re-infect the cells (for a detailed discussion, refer section 2.5.2). 
MDCK cells are the predominant cells used to study influenza viruses in tissue culture, 
because of their ability to withstand the concentrations of trypsin needed for achieving 





Figure 2.5   Localization of ISG15 during influenza B virus infection. Hela cells were 
transfected with plasmid encoding 3XFlag ISG15. 24h post transfection, 
cells were mock infected (panel A), or infected with wild type (panel B) or 
AAA mutant (panel C) influenza B virus. 5h post infection, cells were fixed 
and subjected to immunofluroscence with mouse anti flag and ferret anti 
Memphis antibody to detect flag tagged ISG15 and influenza viral proteins 
respectively. Anti mouse TRITC and anti ferret FITC were used as 
secondary antibodies. DAPI staining was performed to identify the nuclei. 












Figure 2.6 Multiple cycle growth of AAA mutant virus in MDCK cells. 80-90% 
confluent MDCK cells in 60mm dishes were infected with wild type or 
AAA mutant virus at a multiplicity of infection (moi) of 0.001. 1h post 
adsorption, the cells were washed and over layed with opti-MEM containing 
2.5µg/ml N acetyl trypsin and 1% PSG. At specific points after infection, 




responsiveness of the cell to IFN in terms of ability to induce ISG15 and its 
conjugation as well as the ability of the cell line to support multiple cycle growth of 
influenza virus.  
An array of human cell lines was tested for their responsiveness to IFN in terms 
of induction of ISG15 and its conjugation. 293T, A549, Hela tet-on and Calu-3 cells were 
treated with 100 or 1000units of IFN for 36h at 37ºC (figure 2.7). IFN induced free 
ISG15 in 293T cells, but no conjugation was detected. It could be that the enzyme(s) 
responsible for ISG15 conjugation are defective or absent in these cells. In contrast, IFN 
induced robust ISG15 and its conjugation in A549 and Hela tet-on cells. In Calu-3 cells, 
IFN induced less robust ISG15 conjugation than in A549 or Hela tet-on cells. Also, 
ISG15 conjugation can be detected in A549 and Hela tet-on cells but not Calu-3 with a 
shorter 24h treatment with IFN (data not shown).  
Next, the growth characteristics of wild type influenza B virus in A549, Hela tet-
on and Calu-3 cells were studied (figure 2.8). MDCK cells were included as a positive 
control. Viral growth reached titers of 10
8 
pfu/ml in MDCK. Since A549 and Hela tet-on 
cells are very sensitive to trypsin, they were grown on collagen coated plates to enable 
them to bind tighter, and N acetyl trypsin (NAT) was added at a reduced concentration of 
0.1 µg/ml instead of 2.5 µg/ml that is added to MDCK cells. Infection of these two cell 
lines with wild type influenza B virus at a moi of 0.001 failed to produce any virus (data 
not shown). When they were infected with influenza B virus at a moi of 0.01, virus grew 
to titers of ~10
5
pfu/ml. Only Calu-3 cells were able to support growth of virus to titers of 
~10
8
pfu/ml, when infected with a moi of 0.001. The growth of virus in Calu-3 cells more 









Figure 2.7  Induction of ISG15 conjugation in human cell lines. 293T, A549, Hela tet-
on and Calu-3 cells were treated with 100 or 1000 units of human IFNβ for 
36h at 37ºC. Cell lysates were subjected to western blot with anti- ISG15 
antibody to detect the induction of free and conjugated ISG15. Western blot 






Figure 2.8 Multiple cycle growth of influenza B virus in human cell lines. 80-90% 
confluent MDCK and Calu-3 cells were infected with wild type 
B/Yamanashi/98 virus at a moi of 0.001. A549 and Hela tet-on cells were 
grown on collagen coated plates and infected at a moi of 0.01. After 1h of 
adsorption, cells were washed and over layed with opti-MEM supplemented 
with 2.5µg/ml (MDCK and Calu-3) or 0.1µg/ml (A549 and Hela tet-on) N 
acetyl trypsin together with 1% PSG. For A549 and Hela tet-on, NAT was 
supplemented at 36h post infection. At different times post infection, cell 





supported efficient virus growth in the absence of exogenously added NAT (data not 
shown). It is possible that these cells express a trypsin- like protease that is able to cleave  
the viral HA protein. Therefore, for future characterization of the AAA mutant virus, 
Calu-3 cells were chosen since they alone among all the cell types tested supported the 
appropriate multiple cycle growth of influenza B virus. 
 
2.3.7  Characterization of AAA mutant virus in calu-3 cells 
Calu-3 cells were infected at a moi of 0.001 with either wild type or AAA mutant 
virus (figure 2.9), and multiple cycle growth monitored for each virus. The AAA mutant 
virus grows at approximately ten fold slower  rate than the wild type virus, as shown by 
the 12 hour (1.68*10
2
 pfu/ml for AAA virus and 1.3*10
3 
pfu/ml for wild type virus) and 
24 hour (2.9*10
4 
pfu/ml for AAA virus and 1.9*10
5 
pfu/ml for wild type virus) time 
points. At 38 hours post infection, the rate of the wild type virus is 5 times higher than 
that of the AAA mutant virus. These results are in contrast to the results in MDCK cells 
where the AAA mutant virus and wild type virus grew at same rates (figure 2.6).  
 
2.3.8  ISG15 shows species specific variation 
One of the intriguing features of ISG15 is its great variation in sequence across 
species.  A sequence comparison between human, rhesus monkey, canine and mouse 
ISG15 (figure 2.10) shows that canine and mouse ISG15 are respectively only 69% and 
65% identical to human ISG15. However, rhesus monkey ISG15 is much more similar to 






Figure 2.9 Multiple cycle growth of AAA mutant virus in Calu-3 cells. 75-90% 
confluent calu-3 cells in 60mm dishes were infected with wild type or AAA 
mutant virus at a moi of 0.001. After 1h of adsorption, cells were washed 
and over-layed with opti-MEM supplemented with 2.5 µg/ml NAT. Cell 
supernatant was collected at various time points and assayed for viral titer 









Figure 2.10 A sequence alignment of ISG15 orthologs. ISG15 protein sequences from 
human, rhesus monkey, dog and mouse were analyzed by multiple 
alignment using CLC workbench 4.0. Variant residues between the different 
species are shaded in blue with the most intensely shaded residues differing 
the most between the four species. Un-highlighted residues are conserved 
between the species. Stars denote residues in the N terminal domain that are 






identitity took into consideration sequences until the LRLRGG motif for all ISG15 
homologs). The sequence variation of ISG15 is unlike ubiquitin, which is remarkably 
conserved between different species and shows great conservation from yeast to humans. 
Therefore, it is reasonable to predict that there may exist differences in the functions of 
ISG15 from different species. 
 
2.3.9  NS1B binds ISG15 in a species specific manner 
The sequence variation in ISG15, coupled with the fact that AAA mutant virus 
was not attenuated in canine MDCK cells led us to test if ISG15 from different 
mammalian species all bind NS1B. Mouse ISG15 was obtained from Dr. Jon 
Huibregtse’s laboratory. Canine ISG15 (Hsiang, T.Y) and monkey ISG15 were cloned 
from MDCK and Cos7 cells respectively after inducing ISG15 expression with poly I:C. 
Sequence analysis confirmed that these were indeed the canine and monkey ISG15 
proteins. In an in vivo GST binding asay, the binding of NS1B to N terminal GST tagged 
human, mouse, canine or monkey ISG15 was tested (figure 2.11). As expected, NS1B 
bound human ISG15 very well (figure 2.11, lane 2). However, neither the mouse nor 
canine ISG15 bound NS1B (figure 2.11, lanes 3 and 4). Monkey ISG15, which is much 
closer to human ISG15 in terms of sequence, bound NS1B as well as its human 
counterpart (figure 2.11, lane 5). These results show that the interaction between ISG15 
and NS1B is species specific, and may explain the lack of attenuation of the AAA mutant 
virus in MDCK cells. Because canine ISG15 does not bind NS1B, knocking out the 





Figure 2.11 Species specific interaction of ISG15 with NS1B. 293T cells were 
transfected with plasmids encoding GST alone (lane 1) or GST fused to 
human (lane 2), mouse (lane 3), canine (lane 5) or monkey (lane 5) ISG15, 
along with NS1B. 24-36h post transfection, cell lysates were purified over 
glutathione sepharose beads. After washing, the beads were boiled and 
subjected to western blotting with anti NS1B or anti GST anti sera to detect 




results also explain the rescue of wild type influenza B virus in ISG15
-/- 
mice. Because 
NS1B does not bind mouse ISG15, it cannot inhibit the latter’s activity.   
 
2.3.10 Monkey ISG15 as an alternate model system to study influenza B viruses 
 The fact that monkey ISG15 bound NS1B suggested the possibility of using 
monkey systems as a suitable model for studying influenza B virus. For this, it would be 
important to establish that monkey ISG15 is highly similar in structure to human ISG15. 
Since a crystal structure of monkey ISG15 is not available, we undertook to see if the 
interaction between NS1B and monkey ISG15 is similar to the interaction between NS1B 
and human ISG15.   
ISG15 has two ‘ubiquitin- like’ domains (Narasimhan, Wang et al. 2005). The C 
terminal lobe recognizes UBE1L and contains the C terminal LRLRGG motif that is 
conjugated to target proteins (Chang, Yan et al. 2008). To determine if NS1B binds 
ISG15 on its N or C terminal domains, fusion proteins of GST tagged to the N or C 
termini were constructed and tested for their ability to bind NS1B in an in vivo GST pull 
down assay (figure 2.12). The N terminal lobe of ISG15 is sufficient to bind NS1B as 
well as the full length protein while the C terminus does not bind (figure 2.12, compare 
lanes 2, 3 and 4). This observation was also reported by another group of researchers 
(Chang, Yan et al. 2008). To test if the N terminus of owm ISG15 is similarly sufficient 







Figure 2.12 Characterization of interaction between NS1B and monkey ISG15. 
A.293T cells were transfected with plasmids encoding GST alone (lanes 1 
and 8) or GST fused to human ISG15 full length (lane 2), human ISG15 N 
and C lobes (lanes 3-4), monkey ISG15 full length (lane 5) or monkey 
ISG15 N and C lobes (lanes 6-7) along with NS1B wild type (lanes 1-7) or 
AAA mutant (lanes 8-10). 24-36h post transfection, cells lysates were 
purified over glutathione sepharose beads and subjected to western blotting 







tested for their ability to bind NS1B. The N terminus of monkey ISG15 binds NS1B as 
well as the full length monkey ISG15 protein (figure 2.12, compare lanes 5, 6 and 7). 
Further, the AAA mutant NS1B that does not bind human ISG15 also lacks binding 
capability to monkey ISG15 (figure 2.12, lanes 9 and 10). These results taken together 
suggest that the interaction surface between NS1B and monkey ISG15 is similar to its 
interaction with human ISG15. 
 
2.3.11  Role of the hinge region of ISG15 in NS1B recognition 
 In order to map the binding site of NS1B on ISG15, we took advantage of the fact 
that the N terminus of ISG15 is sufficient to bind NS1B. Our first approach was to focus 
on the variant residues between ISG15 orthologs. A sequence comparison of the N 
termini along with hinge of human, rhesus monkey, canine and mouse ISG15 showed a 
total of thirteen residues that were identical to human and rhesus monkey but different 
from mouse and canine (figure 2.10, denoted by stars). However, mutation of each of 
these residues by themselves or in combination in human ISG15 failed to disrupt NS1B 
binding (data not shown).  
In our second approach, we identified the minimum human sequence that when 
introduced into the mouse full length ISG15 was able to impart NS1B binding to the 
mouse protein. A series of human-mouse ISG15 chimeric proteins were constructed 
(figure 2.13A) and tested for their ability to bind to NS1B (figure 2.13B). The 
introduction of amino acids 37 to 80 from human ISG15 into the corresponding region of 
the full length mouse ISG15 was sufficient to impart NS1B binding to the mouse protein 
(figure 2.13B, lane 3). The region from amino acids 37 to 80 comprises part of the N 
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terminal domain (37-74 amino acids of human ISG15) and the hinge region (amino acids 
75-80).  Replacement of the mouse hinge with the human hinge alone was able to impart 
partial NS1B binding (figure 2.13B, lane 5), while the replacement of the region of the N 
terminal domain (amino acids 37-74) was unable to do so (figure 2.13B, lane 4). This 
suggests that the hinge region is crucial in the binding of ISG15 by NS1B. However, the 
human hinge region by itself was insufficient to recover complete binding for the mouse 
full length protein (figure 2.13B compare lanes 1 and 5). A dramatic increase in binding 
occurred when amino acids 63 to 74 of the N terminal domain of human ISG15 was 
added in addition to the hinge of the mouse ISG15 (figure 2.13B lane 6). The surprising 
feature of this region is that the sequence is almost completely conserved between canine 
and human ISG15 with the exception of a glycine at position 66 of human ISG15 that is 
replaced by a cysteine in canine ISG15 (figure 2.14A). We therefore hypothesized that 
replacement of canine ISG15 with just the hinge of human ISG15 should be able to 
restore efficient binding capability to the canine ortholog. Indeed, this was the case, and 
unlike mouse ISG15, canine ISG15 with hinge region from human protein was able to 
restore NS1B binding almost as good as human ISG15 (figure 2.14B, compare lanes 1 
and 3). Further, loss of function mutations in the human hinge also provided more 
evidence for the role of hinge in NS1B binding (figure 2.15). When the three differing 
hinge residues (amino acids 76, 77 and 79) of human ISG15 were mutated to those found 
in mouse hinge, this triple mutant protein no longer was able to bind NS1B (figure 2.15, 




Figure 2.13 Binding of human-mouse ISG15 chimeric proteins to NS1B. A. 
Schematic representation of the human-mouse ISG15 chimeric proteins 
generated. Indicated are the amino acids of human ISG15 that replaced the 
corresponding regions of mouse ISG15. Proteins were tagged at the N 
terminus with GST. Not drawn to scale. B. 293T cells were transfected with 
plasmid encoding NS1B and GST tagged full length human (lane 1) or 
mouse (lane 2) or various chimeras (lanes 3-7). 24h post transfection, cell 
lysates were subjected to purification over glutathione sepharose beads. 
Beads were boiled and subjected to western blotting with anti-NS1B 






Figure 2.14 Minimum requirement for canine ISG15 to bind NS1B. A.Amino acids 
63-80 of human ISG15 are aligned with the corresponding regions of canine 
and mouse ISG15. Blue box represents hinge region, red box represents the 
single differing residue between human and canine ISG15 and green boxes 
represent differing residues between human and mouse ISG15. B. 293T 
cells were transfected with plasmids encoding NS1B along with GST tagged 
human ISG15 (lane 1), canine ISG15 (lane 2) or canine ISG15 with amino 
acids 82, 83 and 85 changed to corresponding amino acids of human ISG15 
(lane 3). Cell lysates were subjected to GST purification and western 
blotting with anti NS1B antibody. NS1B expression in cell extracts prior to 









Figure 2.15 Human ISG15 hinge mutants cannot bind NS1B. 293T cells were 
transfected with plasmid encoding NS1B along with plasmid encoding GST 
human ISG15 wild type (lane 1), or mutants with various residues in the 
hinge region mutated (lanes 2-5). 24h post transfection, cell extracts were 
subjected to purification over glutathione sepharose beads and western 
blotting with anti NS1B antibody. NS1B expression in cell extracts prior to 







K77N or D79S) were also sufficient to disrupt NS1B binding (figure 2.15, lanes 3-5). 
The above results taken together strongly suggest that the hinge region of ISG15 is one of 
the major determining factors of the species specific nature of NS1B binding. 
 
2.3.12  Effect of NS1B on ISG15 conjugation 
2.3.12.1 NS1B does not inhibit in vitro ISG15 thio-ester bond formation with UBE1L 
and UBCH8  
 An early observation in our laboratory was that although free ISG15 is induced in 
influenza B virus infection, ISG15 conjugation does not occur. In an in vitro assay using 
extracts from baculovirus sf9 cells expressing UBE1L or IFN treated A549 cells, it was 
found that the N terminal 1-145 amino acids of NS1B inhibited the first step in the 
conjugation pathway i.e formation of the UBE1L~ISG15 thio-ester bond (Yuan and Krug 
2001). Our efforts to repeat that result using purified UBE1L (kindly provided by Dr. 
Brenda Schulmann) proved unsuccessful. To detect UBE1L and UBCH8 thio-ester bond 
formations with ISG15, purified UBE1L and UBCH8 were incubated with 
32
P labeled 
ISG15. The reactions were stopped, boiled in buffer lacking DTT and analyzed by SDS 
PAGE.  The ISG15~UBE1L thio-ester bond was identified by its dependence on the 
presence of UBE1L (figure 2.16A compare lanes 1 and 2) and its sensitivity to DTT 
(figure 2.16A, compare lanes 2 and 5). Similarly the UBCH8~ISG15 thio-ester bond was 
observable upon the addition of UBCH8 (figure 2.16A, lane 3) and disappeared upon 
addition of DTT (figure 2.16A, lane 6). However, there was no effect on either the 




Figure 2.16 NS1B does not inhibit ISG15~UBEIL and ISG15~UBCH8 reactions. A. 
0.05 µg of 
32
P labeled ISG15 was incubated with 1.4 µg purified UBE1L 
and 1.65 µg of purified UBCH8 in the presence of buffer containing ATP 
for 10 minutes. Samples were prepared in buffer lacking DTT (lanes 1-3) to 
detect E1 and E2 thioester bonds with ISG15. These bonds disappear upon 
addition of DTT (lanes 4-6). B. 10 µg of GST NS1B was pre-incubated with 
32
P labeled ISG15 (lanes 3 and 5) prior to incubation with UBE1L or 
UBCH8. 
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purified NS1B (figure 2.16B, compare lanes 2 and 3; 4 and 5), even when NS1B was 
supplied at a molar excess of 400 as compared to ISG15. These results were subsequently 
confirmed by another group of researchers (Chang, Yan et al. 2008). 
2.3.12.2 Effect of NS1B on ISG15 conjugation in vivo 
 
 We next studied the effect of NS1B on ISG15 and its conjugation in transfection 
experiments. When wild type NS1B was co-expressed with 3xflag human ISG15 along 
with UBE1L, UBCH8 and HERC5 in a quintuple transfection experiment in 293T cells, 
it decreased the intracellular levels of ISG15 conjugates (figure 2.17A, compare lanes 1 
and 2). To test if ISG15 binding is the only cause of this inhibition, the plasmid 
expressing the AAA mutant NS1B instead of the wild type NS1B was transfected (figure 
2.17A, lane 3). Surprisingly, conjugation was only partially restored in the presence of 
the AAA mutant NS1B (conjugation was 40-50% of the conjugation that occurred in the 
absence of NS1B). Similarly, wild type NS1B was able to reduce the levels of owm 
ISG15 conjugates in Hela tet-on cells (figure 2.17B, lanes 3 and 5). Again, the levels 
were partially restored in the presence of the AAA mutant NS1B (figure 2.17B, lanes 4 
and 6).  In a reverse experiment, we tested the effect of wild type NS1B on the hinge 
mutant of human ISG15 which does not bind NS1B (figure 2.17C). However, its 
conjugation is still reduced in the presence of wild type NS1B (figure 2.17C, compare 
lanes 3 and 4). These results taken together suggest that there is another mechanism 
besides binding ISG15 by which NS1B inhibits ISG15 conjugation. Surprisingly, the 
hinge mutant ISG15 was conjugated to a poorer extent when compared to the wild type 
ISG15 (figure 2.17C, compare lanes 1 and 3). 
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Figure 2.17Effect of NS1B on ISG15 conjugation in vivo. A.293T cells were 
transfected with plasmids encoding 3xflag huISG15 along with plasmids 
encoding the conjugation enzymes (E1, E2 and E3). Plasmids encoding wild 
type (lane 2) or AAA mutant (lane 3) NS1B was also co-transfected with the 
above. B. Hela tet-on cells were transfected with plasmid encoding 3xflag 
monkey ISG15 without (lane1) or with (lanes 2-6) plasmids encoding 
conjugation enzymes. NS1B wt (lanes 3,5) or AAA mutant (lanes 4,6) were 
also transfected in increasing amounts. C. 293T cells were co-transfected 
with plasmid encoding 3xflag hu ISG15 wt (lanes 1-2) or 3xflag huISG15 
(76,77,79) hinge mutant (lanes 3-4) along with conjugation enzymes in 
absence  (lanes 1,3) or presence (lanes 2,4) of NS1B wild type. 24-36h post 
transfection, cell lysates were prepared and subjected to immunoblotting 
with the indicated antibodies (A) and with anti flag M2 antibody (B) and (C) 
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It is possible that the hinge, besides determining NS1B binding, is also necessary for 
efficient conjugation to target proteins in human cells.   
2.4  DISCUSSION 
 
 IFN α/β mediated anti-viral activities form a major line of host defense against 
invading viruses. Most viruses, including influenza viruses, have developed strategies to 
counteract the IFN response (Haller, Kochs et al. 2006), (Katze, He et al. 2002), (Levy 
and Garcia-Sastre 2001), (Garcia-Sastre 2001). The NS1 proteins of influenza viruses 
play a crucial role in these counter measures against IFN (Krug, Yuan et al. 2003). The 
NS1 protein of influenza A viruses (NS1A) mediates this protection through both its 
RNA binding domain and effector domain. The NS1A RNA binding domain inhibits the 
IFN induced 2’5’ OAS- RNaseL pathway (Min and Krug 2006). The NS1A effector 
domain inhibits function of the cellular CPSF30, thereby inhibiting the processing of IFN 
pre-mRNA to form mature IFN mRNA in the cytoplasm (Nemeroff, Barabino et al. 
1998), (Das, Ma et al. 2008), and also inhibits activation of PKR (Das, Ma et al. 2008), 
(Min, Li et al. 2007). In contrast, much less is known about how the NS1 protein of 
influenza B virus (NS1B) counteracts the actions of IFN.  ISG15 is one of the most 
strongly induced genes by IFN α/β and is conjugated in an IFN dependent manner to 
hundreds of targets (Zhao, Denison et al. 2005). ISG15 and ISG15 conjugation have been 
shown to inhibit several viruses (Lenschow, Lai et al. 2007), (Lai, Struckhoff et al. 2009), 
(Okumura, Lu et al. 2006), (Okumura, Pitha et al. 2008), (Guerra, Caceres et al. 2008). 
Previously in our laboratory, NS1B was identified as a binding partner for ISG15 (Yuan 
and Krug 2001). In the current study, we show that a mutant influenza B virus which 
 97 
encodes a NS1B that lacks ISG15 binding is attenuated in human but not canine cells, the 
reason being the species specific binding of ISG15 to NS1B. We further extend these 
results by identifying a species specificity determinant in ISG15 for binding NS1B. Our 
results demonstrate the anti-viral activity of ISG15 against influenza B, and also highlight 
the importance of human/primate cells to study influenza B virus and the interaction of its 
NS1B protein with ISG15. 
2.4.1 ISG15 binding site on NS1B 
 
The N terminus of NS1B (amino acids 1-93) constitutes its dsRNA binding 
domain (Wang and Krug 1996). The structure of this domain is very similar to that of 
NS1A, and is in the form of a dimer, with each monomer contributing three alpha helices. 
Alpha helix two from both chains form a groove in which dsRNA binds (Yin, Khan et al. 
2007). Previous mutagenesis data from our laboratory identified the loop between alpha 
helices one and two (loop1) to be the ISG15 binding site (Yuan, Aramini et al. 2002). 
However, subsequently it has been proven that the NS1B structure model on which those 
mutations were based were wrong and the mutations made in that study would disrupt the 
protein structure.  
In our study, the identification of the ISG15 binding site on NS1B has uncovered 
a role for the helix 3 of NS1B as well as a role for amino acid 100. These results are 
consistent with previous data from our laboratory which had implicated both the region in 
between the RNA binding domain (amino acid 93) and amino acid 104 in the ISG15 
binding site. We believe that the structure of the AAA mutant NS1B (which cannot bind 
ISG15) is largely intact since this mutant still retains other characteristics of the wild type 
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protein like its localization to nuclear speckles. Besides, a recombinant virus that encodes 
this mutant NS1B is not attenuated in MDCK cells, proving that the NS1B protein is still 
functionally intact. In contrast, a recombinant virus with the whole NS1B protein deleted 
shows extreme attenuation (Dauber, Heins et al. 2004).  
2.4.2 Human cell culture systems for study of ISG15 and influenza B virus   
 
The predominant cell type used to study influenza viruses in tissue culture are 
MDCK cells, which are derived from a canine kidney source. However, our finding that 
NS1B does not bind canine ISG15 meant that we could not use this cell type to 
characterize the AAA mutant virus. Consistent with these results, the AAA mutant virus 
in not attenuated in MDCK cells.  The influenza viral polymerase is extremely error 
prone and lacks proof reading function; therefore it is reasonable to hypothesize that 
ISG15 binding would not have been preserved if not serving a functional advantage to the 
virus. A sequence alignment of all the 466 NS1B sequences in the influenza resource in 
NCBI website (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) indeed found a 
high degree of sequence conservation of the ISG15 binding site (data not shown). These 
reasons prompted us to screen other human tissue culture systems that might be more 
suitable to characterize the AAA mutant virus.  
The study of influenza viruses in tissue culture is limited by the fact that very few 
cell- types can support a viable multiple cycle growth of the virus. This limitation is due 
in part to the requirement of cleavage of the viral HA molecule for viable infection 
(Lazarowitz and Choppin 1975), (Klenk, Rott et al. 1975). HA cleavage can be carried 
out by either host furin-like or trypsin-like proteases (reviewed in (Webster and Rott 
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1987), (Steinhauer 1999)). Cleavage by the ubiquitous intra-cellular furin-like proteases 
requires a poly-basic cleavage site in HA, which is found in many highly pathogenic 
avian influenza A viruses. These viruses can achieve a multiple cycle growth in many 
cell types. Cleavage by extra-cellular trypsin-like proteases can occur with a mono basic 
cleavage site containing a single arginine in HA. Such a cleavage site is found in most 
human and non pathogenic avian influenza A viruses and all isolates of influenza B 
viruses. Propagation of viruses with mono basic cleavage sites in their HA in tissue 
culture require the exogenous addition of trypsin to the culture media, which very few 
cells can tolerate. Introduction of a poly-basic cleavage site into human influenza A 
viruses was able to render them susceptible to furin-like proteases (Kawaoka 1991), 
(Ohuchi, Ohuchi et al. 1991), although in some cases, the intracellular cleavage 
efficiency is low (Kawaoka 1991). We could not use a similar strategy for influenza B 
virus since a previous study had shown that introduction of a poly-basic cleavage site into 
the influenza B HA was unable to render the molecule cleavable by intra-cellular furin-
like proteases (Brassard and Lamb 1997), suggesting that B/HA is intrinsically different 
from HAs of avian influenza A viruses.  
In our screen to identify a suitable cell line to study influenza B viruses, only one 
cell type, Calu-3, was able to achieve viral titers comparable to MDCK cells, indicating a 
multiple cycle growth of the virus. These cells were previously shown to support growth 
of the 1918 influenza A virus (Tumpey, Basler et al. 2005). Interestingly, Calu-3 cells 
were able to support growth of influenza viruses both in the presence and absence of 
exogenously added trypsin (data not shown; (Tumpey, Basler et al. 2005)). It is possible 
that these cells encode (and secrete) a trpsin-like protease that is able to cleave HA.  
 100 
In Calu-3 cells, the growth of AAA mutant virus was ten fold attenuated in early 
times post infection as compared to the wild type virus. This is in contrast to growth in 
MDCK cells where the AAA virus was not attenuated and in fact grew slightly faster 
(two fold) than wild type in early times post infection.  One reason for the relatively 
modest attenuation could be that the AAA NS1B does not completely relieve the 
inhibition of ISG15 (and its conjugates) that is caused by the wild type protein (for 
detailed discussion on this, refer section 3.6.3). Hence, the attenuation of the AAA virus 
maybe due to the partial inhibition of ISG15 conjugation and also due to the inhibition of 
function(s) of free ISG15. Consistent with the latter possibility, ISG15 is translocated 
inside the nucleus during wild type B virus infection but not during AAA mutant virus 
infection. By mis-localizing ISG15, wild type NS1B might be inhibiting its interaction or 
conjugation to proteins. ISG15 is also secreted as a cytokine and has immune-modulatory 
functions (Recht, Borden et al. 1991), (D'Cunha, Knight et al. 1996), (Owhashi, Taoka et 
al. 2003). Our interpretation of preliminary experiments to study the secretion of ISG15 
were complicated by the fact that we were not able to distinguish between secreted ISG15 
and ISG15 that was released into the media due to cell death upon transfection. It will be 
interesting to test the effects of ISG15 secretion in a co-culture experiment with 
macrophages or NK T cells in presence and absence of NS1B. While suggesting an 
inhibition of free ISG15, our results also do not exclude a role for the inhibition of 
function(s) of pre-existing ISG15 conjugates by NS1B. It is possible that NS1B also 
sequesters pre-existing ISG15 conjugates into nuclear speckles. Indeed, our studies show 
that NS1B is able to bind not only free ISG15 but also the conjugated form. When 
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influenza B virus infects cells where ISG15 conjugates are already present, their nuclear 
sequestration might result in inhibition of the function(s) of ISG15-conjugated protein(s).  
2.4.3 Effect of NS1B on ISG15 conjugation 
 
Several lines of evidence suggest that NS1B reduces the levels of ISG15 
conjugation. We have observed that there is little to no ISG15 conjugation present in wild 
type influenza B infected cells. Also, transfection of a NS1B expressing plasmid reduces 
the intra-cellular levels of ISG15 conjugates in IFN treated cells and also in cells co-
transfected with plasmids expressing the three ISG15 conjugation enzymes, UBE1L, 
UBCH8 and HERC5. Previous studies in our lab using UBE1L expressing insect Sf9 cell 
extracts showed that NS1B is able to inhibit the formation of the UBE1L~ISG15 
thioester bond (Yuan and Krug 2001). However, we and other groups (Chang, Yan et al. 
2008) have subsequently been unable to repeat this result using an in vitro assay using 
purified UBE1L. We also have found that NS1B is similarly unable to inhibit the second 
step in the pathway, i.e UBCH8~ISG15 thiol ester bond formation. The C terminal 
domain of ISG15 is sufficient to form thiol ester bonds with both UBE1L and UBCH8, 
while the N terminal domain is involved in increasing the repertoire of target conjugates 
presumably by recognizing the ISG15 ligase (Chang, Yan et al. 2008). Since NS1B binds 
ISG15 on its N terminus, we hypothesize that NS1B interferes with the last step in the 
conjugation pathway, which involves HERC5. The exact mechanism of the inhibition 
remains unresolved. The inhibition could either be at the step of HERC5~ISG15 thiol 
ester formation or at the level of target recognition by HERC5. Currently an in vitro 
system for the detection of HERC5~ISG15 thiol ester bond formation is unavailable 
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because of the difficulty in purifying biologically active HERC5 protein (Dastur, 
Beaudenon et al. 2006). Development of such an assay would help in testing this 
hypothesis directly.  
Surprisingly, we found that binding of ISG15 is not the sole mechanism by which 
NS1B inhibits ISG15 conjugation. Two experiments support this conclusion. First, when 
a plasmid expressing the AAA mutant NS1B is co-transfected with plasmids expressing 
the enzymes of the ISG15 conjugation system, only a partial recovery of ISG15 
conjugation is observed. Second, wild type NS1B is able to partially suppress the 
conjugation of an ISG15 (hinge) mutant that lacks binding capability to NS1B.  These 
results indicate that the full effects of NS1B on the ISG15 conjugation system are not 
completely reversed by simply knocking down ISG15 binding function of NS1B. These 
observations explain why the replication of the AAA mutant virus in Calu-3 cells was 
only ten fold slower than that of the wild type virus. Future experiments will be directed 
at identifying the NS1B sequence(s) that mediate the complete inhibition of ISG15 
conjugation, and determining whether a influenza B virus expressing such a mutant 
NS1B protein is more attenuated than the AAA mutant described here. 
2.4.4 Species specific interaction of ISG15 with NS1B 
 
 A significant finding in our research is that the binding between ISG15 and NS1B 
is species specific. NS1B binds human and African green monkey ISG15 proteins but not 
mouse or canine ISG15 proteins. We also identified the hinge region between the N and 
C terminal ubiquitin-like domains of ISG15 as the principal species specific determinant 
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for NS1B binding. In addition to forming possible contacts with NS1B, the hinge region 
in human and monkey ISG15 may be orienting the two ubiquitin-like domains in such a 
way as to allow NS1B access to the binding site on the N terminal domain, while in 
canine and mouse ISG15 proteins, the orientation of the two ubiquitin-like domains 
might block NS1B from the binding site. In fact, our results suggest that at least part of 
the binding pocket is conserved between species and is composed of the β sheet 
immediately preceding the hinge region on the N terminal domain. Another surprising 
finding in our study is that the human ISG15 with hinge from mouse ISG15 is not only 
able to inhibit NS1B binding, but also reduces the mutant’s ability to conjugate to target 
proteins. Other studies have proposed that the N terminal region of ISG15 is responsible 
for recognizing HERC5 (Chang, Yan et al. 2008), thereby facilitating ISG15 conjugation. 
However our results suggest that the hinge plays a large role in this process.  
ISG15, unlike ubiquitin, is not very well conserved among different species and 
shows wide variation in sequence. Many genes involved in innate immunity show great 
divergence between species due to evolutionary pressure. For example, TRIM5α is a 
protein that inhibits HIV-1 infection by interfering with virus un-coating in old world 
monkeys but not in humans (Stremlau, Owens et al. 2004). The HIV protein Vif is able to 
counter act another anti-viral protein APOBEC3G in humans and chimpanzees but is 
ineffective against mouse, rhesus macaque and African green monkey orthologs. 
Similarly, SIV Vif is able to inhibit African green monkey but not human APOBEC3G  
(Mariani, Chen et al. 2003). Paramyxoviruses also show a differential ability to inhibit 
the IFN response in a species specific manner. STAT-2 is degraded by paramyxovirus 
simian virus 5 (SV5) in human but not the mouse cells, leading to the inability of virus to 
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inhibit IFN α/β signaling in mice resulting in virus restriction in this organism (Parisien, 
Lau et al. 2002). Influenza B virus has been isolated from only humans, and canines and 
mice are not natural hosts. Consequently, it is not surprising that the NS1B protein has 
evolved to bind specifically to human ISG15 (and its primate progenitors), but not to 
canine and mouse ISG15 proteins. For this reason, mouse and canine ISG15 proteins 
would be expected to be effective in their anti-viral activities against influenza B virus 
since NS1B does not bind these molecules. Indeed this is what was found when influenza 
B virus was rescued in ISG15
-/- 
mice (Lenschow, Lai et al. 2007), suggesting that in these 
animals, NS1B was ineffective in countering the anti-viral properties of ISG15. Recently, 
it has also been shown that influenza B virus is rescued in UBE1L 
-/- 
mice (Lai, 
Struckhoff et al. 2009). At present, it is not known if NS1B inhibits conjugation of mouse 
ISG15 in mouse cells. Taken together, our studies highlight the unsuitability of mouse 
models of ISG15 as well as the commonly used MDCK cells to study influenza B virus.   
Since NS1B binds the more closely related monkey ISG15, we propose old world 
monkeys (owm) such as rhesus macaques as a more suitable animal model to study 
influenza B virus. Owm ISG15 was recently shown to conjugate much stronger than 
either human or mouse. This is due to the ability of owm ISG15 to be conjugated by the 
E1 enzyme of ubiquitin (Pattyn, Verhee et al. 2008). A suitable ‘owm’ cell line which is 
able to support multiple cycle growth of influenza B virus could be a valuable tool in 
better understanding the interplay between ISG15 and influenza B virus. One African 
green monkey cell line, Vero, has been used to grow high titers of influenza viruses. 
However, these cells do not respond to IFN since they lack IFN genes. Treatment of these 
cells with Poly I:C also did not induce much ISG15 (data not shown). Another African 
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green monkey cell line Cos7 induced ISG15 upon treatment with Poly I:C but was not 
able to reach high titers of virus growth. Further screening will be important to identify a 
monkey cell line that has a robust IFN response as well as the ability to support multiple 
cycle influenza B virus growth.  
Another line of useful experiments would be to adapt the MDCK cells to study 
influenza B virus, for example, by expressing human ISG15 in these cells to see if the 
AAA mutant virus is attenuated. However, high transfection efficiencies could not be 
achieved in MDCK cells and our efforts to make a stable MDCK cell line to 
constitutively express human ISG15 proved toxic to the cells. Hence, it might be 
necessary to make a stable cell line with ISG15 expression under an inducible promoter. 
An alternative could be to engineer the virus itself to over express ISG15 in the infected 
cells. A similar strategy was used for Sindbis virus to show the sensitivity of that virus to 
virally expressed ISG15 (Lenschow, Giannakopoulos et al. 2005). While influenza A and 
B viruses contain eight genomic segments, influenza C virus contains only seven, since in 
the latter’s case, the functions of both the HA and NA are carried out by a single enzyme 
HEF. Recently, a recombinant influenza A virus was generated that contained the C/HEF 
protein, thereby allowing the expression of a reporter GFP plasmid from the NA segment 
(Gao, Brydon et al. 2008). Theoretically, such an approach should also work for 
influenza B virus, and would afford a system in which ISG15 or any other protein of 
interest could be expressed from the virus itself.  
Structural studies are required to provide insights into the exact mode of binding 
between ISG15 and NS1B. It would be interesting to see if a small region of human 
ISG15 would be able to assume a three dimensional structure to bind NS1B. If so, then 
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we could test to see if over expression of that fragment of ISG15 will be enough to inhibit 
influenza B virus. Such an experiment has precedence in influenza A virus where a small 
fragment of the cellular CPSF 30 protein was expressed in cells to inhibit the virus (Twu, 
Noah et al. 2006). Such strategies could have future therapeutic implications to inhibit 
influenza B viruses.  
In summary, my research has identified important determinants of the interaction 
between NS1B and ISG15. My results provide the first example of a species (human) 
specific function for a protein encoded by this predominantly human influenza B virus. It 
also raises exciting possibilities about differences in functions of the ISG15 system in 
different species. Future experiments will nevertheless be important to further 
characterize the different levels of regulation of NS1B on the ISG15 system and the 





CHAPTER 3: Studies on the intra-nuclear localization of the influenza 




 Influenza viruses are unique among other negative strand segmented RNA viruses 
in that they replicate in the nucleus of the infected cell. Therefore, the viral RNA along 
with proteins involved in its replication (like viral polymerase complex and NP) must be 
transported inside the nucleus. After replication is complete, the viral RNP complex must 
be exported out of the nucleus with the help of the NS2 protein. Therefore, many of the 
influenza viral proteins contain nuclear localization signals that traffic them to the 
nucleus (reviewed in (Boulo, Akarsu et al. 2007)).  
NS1 proteins of influenza viruses are multi-functional proteins. NS1 of influenza 
A virus (NS1A) has been characterized in depth and has been found to play a wide range 
of roles during infection, from inhibition of host anti-viral responses to regulating viral 
polymerase function (reviewed in (Hale, Randall et al. 2008)). Some of these functions 
are presumably carried out in the cytoplasm (like inhibition of PKR); however other 
functions are carried out in the nucleus. Indeed, a crucial function of NS1A is to inhibit 
the processing of host pre-mRNAs, thereby preventing the nuclear export of mature host 
mRNAs (Noah, Twu et al. 2003), (Das, Ma et al. 2008). NS1A carries out these functions 
in the nucleus by binding two nuclear proteins, CPSF30 and PABII. These factors are 
involved in 3’ end processing of cellular mRNAs, and their functions are inhibited by 
binding to NS1A (Nemeroff, Barabino et al. 1998), (Chen, Li et al. 1999). Nuclear 
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targeting of NS1A from human viruses is mediated by two nuclear localization signals 
(NLSs) present in the protein (Greenspan, Palese et al. 1988). NLS1 is a classic mono-
partite signal (consisting of 4-6 basic amino acids), and is present within the N terminal 
dsRNA binding domain which also coincides with the binding site for dsRNA (R38 and 
K41). NLS2 is present in the C terminal effector domain (amino acids 219-230). Inside 
the nucleus, NS1A is mostly present in the nucleoplasm, but also accumulates inside the 
nucleolus (NLS2 also functions as a nucleolar localization signal (NoLS)). Both NLS1 
and NLS2 mediate binding to importin α, and it has been shown that NS1A binds all six 
isoforms of importin α (Melen, Kinnunen et al. 2007).  
NS1B protein of influenza B virus also contains a monopartite NLS which 
overlaps with its dsRNA binding region, and we and others have shown that the NS1B 
protein is imported into the nucleus (Schneider, Dauber et al. 2009). However unlike 
NS1A, it lacks a NLS/NoLS in the C terminus. While at least some of the nuclear 
functions of NS1A have been elucidated (namely inhibition of 3’ end processing of 
mRNAs, regulation of viral polymerase function), little is known about the nuclear 
function(s) of NS1B. In fact, the only known interacting partner for NS1B is the cellular 
factor ISG15, which is a cytoplasmic protein (Loeb and Haas 1994). Therefore, much 
research is required to understand the nuclear functions of NS1B. To begin to understand 
NS1B’s nuclear functions, we carried out studies on the localization of NS1B. We found 
that NS1B is localized to the nucleus during early stages of infection while at later stages 
is present in the cytoplasm. Inside the nucleus, it accumulates in intra-nuclear 
compartments called SC35 speckles. This is a unique property of NS1B as it is not shared 
with NS1A. Splicing or SC35 speckles are so called because of their characteristic 
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accumulation of the splicing factor SC35. They are also enriched in other splicing factors, 
along with RNA and other proteins involved in RNA metabolism (reviewed in (Lamond 
and Spector 2003)). We show that targeting of NS1B to speckles does not require other 
viral proteins and is not RNA mediated. Furthermore, we found that nuclear speckle 
localization of NS1B is mediated by sequences in both the N-terminal RNA-binding 
domain and the C terminal effector domain. 
3.2 MATERIALS AND METHODS 
Cell lines 
 
 MDCK, A549 and Hela cells were cultured in DMEM (GIBCO®) supplemented 
with 10% fetal bovine serum (GIBCO®) and 1% PSG (penicillin streptomycin 
glutamate) at 37ºC with 5% CO2 /95% air atmosphere. 
Plasmids and transfection 
 
GFP tagged NS1B plasmids were made by cloning the DNA encoding NS1B into 
the pEGFP-C1 plasmid (Clonetech) using Bgl2 and Hind3 restriction sites on the vector. 
For insertion of NLS from the large T antigen of SV40 virus (SV40-NLS), the NLS was 
added to the N terminus of NS1B by a two step PCR reaction where the 5’ primer in the 
first step of PCR contained part of the sequences of the NLS overlapped with the 5’ 
primer used during the second step of the PCR. The DNA for NLS-NS1B was then 
cloned downstream of GFP in the pEGFPC1 vector using Bgl2 and Hind3 restriction 
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enzyme sites. The plasmids encoding GFP-NS1B were transfected into Hela cells in 
using Mirus transfection reagent following the manufacturer’s protocol. 
Viruses and infection 
 
 Wild type influenza B/Yamanashi/1998 virus was generated by reverse genetics 
and amplified in ten day old embroynated chicken eggs as described in chapter 2 (refer 
materials and methods). N terminal 3xflag tagged NS wild type influenza B virus was 
generated by J.W. Park (see chapter 2, materials and methods for details) and amplified 
in MDCK cells. 
In vitro dsRNA binding assay 
 
GST NS1B protein(s) purication: For purification of GST NS1B proteins in bacteria, 
DNA for NS1B 1-104, R50A, R53A and R50AR53A in 1-104 background were cloned 
into pGEX4T2 vector using BamHI and XhoI sites on the vector and Bgl2 on 5’ end and 
XhoI on 3’ end of the insert. The proteins were then expressed and purified from a 1 litre 
culture of E.coli as described (chapter 2, materials and methods). 
Probe preparation: A 55bp β globin template was generated by PCR from a 210bp β 
globin template, such that the PCR product had sites for the restriction enzymes BamH1 
or EcoR1, as well as T7 or SP6 polymerase site on each end. An EcoR1 or BamH1 digest 
of the PCR product was used as template for transcription by SP6 or T7 polymerase 
(Invitrogen) respectively. 
32
P labeled single stranded RNA were generated by 
incorporation of 
32
P labeled UTP in the in vitro transcription by the RNA polymerase in a 
30µl reaction. To form dsRNA, the transcripts (in 10mm HEPES, pH7.6 and 50mM 
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NaCl) were heated to 90ºC for two minutes and allowed to anneal to each other by slow 
cooling to room temperature. 
dsRNA binding assay: Increasing concentrations  (0.5, 1 and 1.5 µg) of NS1B wt, R50A, 
R53A or R50AR53A in 1-104 background that were purified from E.coli and GST tag 
cleaved off were incubated with 5 µl of 
32
P labeled dsRNA in the presence of binding 
buffer (50mM Tris-Cl pH 8.0, 50mM KCl, 50mM glycine, 2.5mM DTT, o.5 units/µl 
RNasin (Promega) and 50mg/ml of E.coli tRNA (Promega)) for 30 minutes at room 
temperature. The reaction was stopped by addition of 6X RNA loading buffer and the 
components separated on a 6% non-denaturing polyacrylamide gel. The labeled probe 
and its complexes were detected by autoradiography.   
Immunofluroscence 
 
Immunofluroscence was performed as described in materials and methods (chapter 2). 
3.3 RESULTS 
 
3.3.1 NS1B shows unique sub-cellular localization  
 NS1A is a nuclear protein and has been shown to accumulate inside the nucleolus 
at certain times during infection. NS1B contains a nuclear localization signal (NLS) in its 
N terminal RNA binding domain that is analogous to NLS1 in NS1A (figure 3.1A, boxed 
residues). We therefore tested to see if NS1B also localizes to the nucleus. NS1B 
localization was observed during infection of MDCK cells using anti NS1B antibody. 
NS1B does enter the nucleus and interestingly, it showed distinct dot-like accumulation 
(figure 3.1B). We have shown that NS1B has some species specific functions, namely 
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binding to human but not canine ISG15 (refer chapter 2). Since influenza B virus is 
predominantly a human virus, we wanted to confirm that this intra nuclear localization 
was not unique to MDCK cells but was also observed in human cell lines. The polyclonal 
NS1B antibody has high background during immunofluroscence; therefore we utilized a 
recombinant B/Yamanashi/1998 virus which expresses a NS1B with a 3xflag tag at its N 
terminus (developed by J.W. Park). Such N terminal tagging is not detrimental to the 
virus, and the NS1B protein is efficiently detected when immunoblotted with anti flag 
antibody (data not shown). Immunofluroscence with anti flag antibody showed that the 
3xflag tagged NS1B showed similar intra nuclear localization in both A549 and MDCK 
cells (figure 3.2). Similar localization was also observed in Hela cells (chapter 2, figure 
2.4). Hence, unlike ISG15 binding which is species specific, the intranuclear localization 
of NS1B is conserved across species. Further, it was observed that at early times post 
infection (5h), NS1B is nuclear (figure 3.2A), but at later times (9h), becomes 
predominantly cytoplasmic (figure 3.2B). This is very unlike NS1A protein which is 
nuclear for most of the influenza A viral life cycle.   
 
3.3.2  NS1B localizes to SC35 speckles due to an intrinsic property of the protein 
Next, we wanted to determine if the intra-nuclear localization of NS1B is intrinsic 
to the protein or requires the action of other viral proteins. To test this, a plasmid 
expressing NS1B with a N terminal GFP tag was constructed and transfected into Hela 
cells. While the control GFP protein was distributed all over the cell (figure 3.3A), GFP-






Figure 3.1  NS1B is a nuclear protein A.A sequence alignment of amino acids 31-48 of 
NS1A and 43-60 of NS1B. Boxes represent amino acids in NS1A (R35, R38 
and K41) that are required for importin-α binding and the corresponding 
residues in NS1B. B. MDCK cells were infected with wild type influenza 
B/Yamanashi/98 virus. 5h post infection, cells were fixed and subjected to 
immuno-fluroscence with anti NS1B antibody. Secondary antibody used 








Figure 3.2 NS1B localizes to nucleus during early phases of infection. A549 or 
MDCK cells were infected with N terminal 3xflag tagged wild type NS 
influenza B virus. 5 (A) or 9 (B) hours post infection, cells were fixed and 
subjected to immunofluroscence with mouse anti flag antibody to detect 







The nucleus contains many sub-nuclear compartments which are identified by the 
presence of characteristic proteins. Immuno-fluroscence with an antibody that detected 
the splicing factor, SC35, showed a high degree of overlap with the GFP-NS1B signal 
(figure 3.3B, merge panel). These results prove that NS1B localizes to SC35 or splicing 
speckles and that this localization does not depend on the actions of other viral proteins. 
SC35 speckles are alternatively called splicing speckles and are enriched in splicing 
factors as well as RNA binding proteins, RNA polymerase II subunits as well as other 
RNA processing factors. Many of these factors are found in more than one nuclear sub-
compartment; however SC35 characteristically accumulates in splicing speckles and are 
excluded from other compartments like para-speckles.  
 
3.3.3  RNA binding property of NS1B is not required for speckle localization 
NS1B is an RNA binding protein and shares a structurally conserved N terminal 
dsRNA binding domain with NS1A. Splicing speckles are comprised of over 130 
proteins, many of which are RNA-binding proteins and are involved in various steps of 
RNA metabolism. Besides, speckles also contain a stable population of RNA. These 
reasons led us to test if the dsRNA binding property of NS1B is responsible for its 
speckle localization.  
3.3.3.1 Residues required for dsRNA binding of NS1B 
 
 Earlier studies on the dsRNA binding domain of NS1B had identified the residues 






Figure 3.3 NS1B localizes to SC35 speckles. Hela cells were transfected with GFP 
empty vector (A) or GFP NS1B (B). 24h post transfection, cells were fixed 
and immunofluroscence was conducted with anti SC35 as primary antibody 
and anti mouse conjugated to TRITC as secondary antibody. GFP signal 
was detected with UV light. The merge panel shows the overlap of GFP and 











Figure 3.4   Residues required for dsRNA binding of NS1B. 5µl of 
32
P labeled dsRNA 
probe (lane 13) was incubated with decreasing concentrations of bacterially 
purified GST NS1B wild type (lanes 10-12), R50A (lanes 7-9), R53A (lanes 
4-6) or R50AR53A (lanes 1-3) proteins for 30 minutes at RT. Reactions 
were stopped by adding 6X loading buffer and complexes were separated on 
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and structural studies of NS1A and NS1B predict that R50 and R53 of NS1B are 
analogous to R38 and K41 of NS1A respectively. A crystal structure of the RNA binding 
domain of NS1A bound to RNA shows that R38 penetrates the RNA helix and is the 
most important residue for dsRNA binding. Consistent with this prediction, a single 
mutation R38A in NS1A is sufficient to completely disrupt dsRNA binding of the wild 
type protein. Based on these data, we wanted to test if a single mutation of either R50 or 
R53 of NS1B is sufficient to disrupt its dsRNA binding. Bacterially expressed GST 
NS1B wild type, R50A, R53A or double mutant R50AR53A were incubated with a 
32
P 
labeled 55bp dsRNA generated by in vitro transcription from a β globin template (see 
Materials and Methods). The resulting complexes were separated in a native poly-
acrylamide gel, and the migration of the radio-labeled dsRNA was detected by 
autoradiography. NS1B wild type protein shifted all the dsRNA into a slower migrating  
complex (figure 3.4, lanes 10-12). Although most of the dsRNA was unbound when 
incubated with either of the single mutant, R50A or R53A, weak binding could still be 
detected (figure 3.4, lanes 4-9). In contrast, the double mutant R50AR53A NS1B lacked 
detectable dsRNA-binding activity as most of the probe remained unbound (figure 3.4, 
lanes 1-3). These results indicate that for full knockdown of dsRNA binding capacity of 
NS1B, both these residues must be mutated.  
3.3.3.2 Localization of dsRNA binding mutant of NS1B 
 
 A plasmid expressing GFP-NS1B R50A/R53A was transfected into Hela cells 
(figure 3.5A). Since this region also encodes the nuclear localization signal, most of the 
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protein was mis-localized to the cytoplasm. Some of the protein still entered the nucleus 
and accumulated in speckles. To conclusively see if this mutant localized to speckles, a 
NLS sequence was fused at the N terminus. The NLS from SV40 large T antigen is a 
classical monopartite nuclear localization signal and has been shown to function in ‘trans’ 
when attached to any reporter protein. We inserted the NLS between the GFP and the 
NS1B R50A/R53A sequence as shown in figure 3.5B. The GFP-NLS-R50AR53A protein 
was efficiently transported into the nucleus and accumulated inside speckles (figure 
3.5B), proving conclusively that dsRNA binding is not responsible for mediating speckle 
localization of the NS1B protein.  
3.3.4.  Both N terminal and C terminal domains of NS1B contribute to speckle 
localization  
In some proteins, the nuclear and speckle localization signals cannot be separated. 
However, our finding that even upon mutation of the nuclear localization signal, NS1B 
accumulates in the speckles when supplied with an NLS proves that in NS1B at least, the 
two signals can be separated. To identify the region of NS1B that is responsible for 
speckle localization, we first used plasmids expressing either GFP-NS1B (1-93) or GFP-
NS1B (1-104), and observed the localization of the tagged proteins inside the cell (figure 
3.6A). Since these fragments contain the NLS, they are predominantly nuclear in 
localization. The nuclear proteins accumulated in speckles, but some of these proteins 
were also in the nucleoplasm. Localization of these two NS1B fragments to the speckles 





Figure 3.5 Localization of dsRNA binding mutant of NS1B. Hela cells were 
transfected with GFP tagged NS1B (R50AR53A) (A) or GFP-NLS-
NS1B(R50AR53A) (B). 24h post infection cells were fixed and stained with 
DAPI to observe the nuclei or observed under UV light for GFP fluroscence. 






Figure 3.6 Both N and C terminal domains of NS1B contribute to speckle 
localization. Hela cells were transfected with the indicated plasmids 
expressing GFP tagged NS1B constructs. 24h post transfection, cells were 
fixed observed for GFP fluroscence under UV light. To observe SC35 
speckles, fixed cells were subjected to immunofluroscence with mouse anti 
SC35 primary antibody and anti mouse secondary antibody conjugated to 





These results suggested that the C-terminal effector domain of NS1B also 
contributes to the localization to nuclear speckles.  The NS1B effector domain lacks a 
NLS, and as result. GFP-NS1B (95-281) accumulates in the cytoplasm (data not shown). 
Therefore, we added the NLS from SV40 large T antigen between GFP and NS1B (95-
281) (figure 3.6B). This protein localized to the nucleus, and showed slight enrichment in 
speckles (figure 3.6B). However, the localization of this NS1B domain was poor 
compared to the full length NS1B protein. Our results taken together suggest that speckle 
targeting signal is contributed by regions within both N and C terminal domains of NS1B 
protein.  
 
3.4  DISCUSSION 
 
 The nucleus is a highly compartmentalized structure as shown by electron 
microscopy, with certain regions more electron dense as compared to the surrounding 
nucleoplasm. Several of these intranuclear compartments have been described in the 
literature, e.g., nucleolus, cajal bodies (CBs), promyelocytic leukemia (PML) bodies, 
gems, paraspeckles and splicing speckles (reviewed in (Spector 1993)). Each of these 
compartments has a complex composition and is composed of many different proteins 
and RNA populations. SC35 or splicing speckles are enriched in splicing factors like the 
SR protein SC35, and along with other RNA processing factors (Saitoh, Spahr et al. 
2004). The function(s) of SC35 speckles have been the subject of debate, but it is now 
widely accepted that they act as storage/assembly sites for splicing/RNA processing 
factors from where the latter are recruited to sites of active transcription or splicing 
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(reviewed in (Lamond and Spector 2003)). Speckles contain more than 130 proteins as 
identified by mass spectrometry (Saitoh, Spahr et al. 2004). Analysis of these proteins did 
not reveal any single sequence or domain that was responsible for speckle localization. 
Several different targeting signals have been reported; in certain cases, specific sequences 
like the SR domain of certain SR proteins have been shown to translocate non-speckle 
localizing proteins into speckles when attached to them (Hedley, Amrein et al. 1995).  
It is intriguing that the NS1B protein is found in speckles. Unlike NS1A, NS1B 
has no documented effect on RNA processing or splicing. Indeed, NS1A binds PABII, 
which is a speckle associated protein; however it is not found in speckles (Chen, Li et al. 
1999). It is probable that NS1B is binding some protein that is localized to speckles. One 
of the ways to understand the function of speckle localization of NS1B would be to study 
the characteristics of a mutant protein that can no longer associate with speckles. Study of 
a recombinant virus that encodes such a mutant would be able to give insights as to 
whether speckle localization of NS1B is important to the virus. However, our efforts to 
identify a specific region that is responsible for speckle targeting have so far been 
unsuccessful. Our experiments suggest that both the N and C terminal domains of NS1B 
are involved in targeting since each alone only retains weak association with speckles. It 
is possible that in the three dimensional structure, a single surface that is responsible for 
localization has contributions from both the domains. Alternatively, there could be two 
separate surfaces that are additive and together mediate efficient localization. Our data 
suggest that the site(s) on both the domains need to be mutated together to completely 
eliminate speckle localization. However, our efforts to identify the region within the N 
terminal domain were not successful. Also, currently the structure of the C terminal 
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domain or full length NS1B is not available; therefore any mutation that is made in that 
domain carries the risk of disrupting the protein structure.  
In the event that sites of NS1B that mediate speckle localization are not identified, 
other approaches might be taken to understand the reason for this unique localization 
property. One such approach could be to identify the protein factor(s) to which the NS1B 
protein is binding to in the speckle. A biochemical strategy for the purification of 
speckles from mouse liver has been developed and has been used to identify the protein 
composition of speckles through mass spectrometry (Mintz, Patterson et al. 1999). It 
might be useful to do an in vitro affinity pull down of an extract of the mouse liver 
speckles using the RNA binding mutant of NS1B to see if any protein(s) are pulled down 
by NS1B. Since the speckle localization of NS1B is conserved across species, this mouse 
extract is probably suitable for identifying the speckle interacting protein(s). Once such 
interacting speckle proteins are identified, it could be tested as to whether NS1B 
influences their function in any way. 
It will also be interesting to see if other influenza B viral proteins like the 
polymerase or the viral RNA itself localizes to the speckles. It has been observed that the 
small antigen of the hepatitis delta virus is recruited to the speckles to aid viral RNA 
transcription (Bichko and Taylor 1996). It might be that NS1B has as yet unidentified 
functions in the splicing of viral mRNAs that leads to its association with host splicing 
factors. In addition, it is possible that NS1B localizes to the speckles to inhibit the action 
of certain host proteins that carry out antiviral functions. This is analogous to the 
situation with the NS1A protein, which inhibits 3’ end processing of host pre-mRNAs so 
that antiviral proteins are not made (reviewed in (Krug, Yuan et al. 2003)). Another 
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possibility is that NS1B, by binding to certain speckle or RNA processing factors is 
hijacking or regulating a host pathway for the benefit of the virus. Such hijacking of 
cellular processes is a well known strategy used by viruses to aid their replication.  
This study has clarified important questions that were not answered by a previous 
study. For example, my research has shown that the speckle localization signal can be 
distinguished from the NLS, does not depend on dsRNA binding of NS1B and is 
contributed by both N and C terminal domains of NS1B. Together, the results presented 
in this study have further enhanced our knowledge of the functions of NS1B protein. 
Nevertheless, future research is needed to uncover the role(s) of NS1B in the nucleus, 
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